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Abstract

Central nervous system (CNS) disorders are becoming a major societal problem.
Examples of well-known CNS disorders are: neurodegenerative disorders such as
Parkinson's, Huntington's and Alzheimer’s diseases, epilepsy/seizures, addiction,
bipolar disorder, catalepsy, meningitis, migraines, attention deficit/hyperactivity disorder
(ADHD), and multiple sclerosis. CNS disorders can be caused by various factors and
therefore can affect ages, genders and races of all.
The population of patients with CNS disorders is increasing and a significant
percentage of patients have symptoms that are not controlled by existing treatments. In
addition, since CNS disorders are chronic disorder, there is no cure and thus the
patients have to live with the condition with possibility of medications that can well
control the symptoms. In contrary, the development of CNS-drugs is not adequately fast
enough mainly due to the complexity of pathologies and the low success rate in regard
to new drug approval by federal institutions such as Food and Drug Administration
(FDA) of the US. Designing CNS-drugs is very challenging and one of the biggest
challenges is to overcome the blood-brain barrier (BBB). Due to the BBB, the
physiochemical property criteria for CNS-drugs are narrower and more specific than
general therapeutic compounds (i.e. Lipinski’s rule of five), and hence the development
of CNS-drugs experiences a major delay and low success rate.

xix

Carbohydrates can be useful because of their multi-functionalizable structures and
high biocompatibility; properties suitable for CNS-drugs. As carbohydrates are most
abundant natural compounds, they are often readily available at low cost. In addition,
regio- and stereospecific modification can modify a molecule for the best fit to a target
receptor. Moreover, carbohydrates can manipulate glucose transporters to pass through
the BBB. However, not many carbohydrate drugs are available due to synthetic
complexity and difficulties of regio- and/or stereospecific reactions. Therefore, we are
interested in utilizing carbohydrate compounds for treatments of CNS disorders. Hence,
we have developed a novel carbohydrate template for CNS-drugs and a series of
analogs were prepared to study structure activity relationship (SAR) of our carbohydrate
analogs on CNS receptors.
Despite the synthetic challenges, we have successfully prepared a library of
novel carbohydrate analogs. The physicochemical properties of all the analogs were
calculated to show that our analogs theoretically have high bioavailability for oral
administration. In addition, the said analogs were tested against over 50 CNS receptors
and the in vitro testing of the said compounds has revealed that structural modifications
significantly change the biological activities as well as target receptors. Furthermore, our
active compounds showed high selectivity to a specific receptor, implying that we can
potentially reduce side effects that are associated with undesired binding activities.
Ultimately, our novel carbohydrates have shown a great potential for treatments of
various CNS disorders, and it can be further investigated for development of new drugs
for the treatments of CNS disorders.

xx

Chapter 1

An Introduction to Central Nervous System Disorders and the Drugs
Used to Treat Them

1.1.

Introduction

Central nervous system (CNS) disorders are disorders affecting the structure
and/or function of the CNS, which comprises essentially all of the brain and the spinal
cord. It has been a long believed fundamental principle in neuroscience, that neurons
are generated only in the prenatal phase of human development, and therefore, any
damages occurring in the CNS are permanent after birth.1 However, in 1966, Altman
reported that neuroregeneration can occur in the intact adult mammalian brains.2 His
conclusions were based upon observation on neurogenesis of intact adult mammalian
cells in the hippocampus and other regions of the brain in rodents. In other words,
damage in the adult mammalian brain still disturbs neuroregeneration therein, and the
recovery would be insufficient for total cure. Hence, CNS disorders are still chronic
conditions to this day and thus the conditions perpetually need to be controlled with
appropriate treatments. The treatments of CNS disorders include surgery, medication
(oral or other administration), rehabilitation, radiation therapy and so forth. The method
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of treatment is chosen according to the cause and the symptoms but, by and large,
orally administered medication is the easiest and most used method of treatment.
CNS disorders are very diverse disorders because of the complexity of the brain.
Examples of CNS disorders include, but are not limited to, neurodegenerative disorders
(e.g. Parkinson’s, Alzheimer’s and Huntington’s disease), multiple sclerosis (MS),
bipolar disorder, attention deficit/hyperactivity disorder (ADHD), autism, meningitis,
epilepsy/seizures, migraines, depression and addiction. CNS disorders can be
congenital (e.g. structural defects, autoimmune system disorder, etc.), acquired by
physical damages (degeneration, stroke, tumors, infections, etc.) or acquired by mental
damages (i.e. trauma). A particular condition can be caused by different factors and a
cause can result in different and/or multiple disorders. Furthermore, patients with other
health conditions are more prone to certain CNS disorders and vice versa, directly and
indirectly.
As a typical example of direct association of a health condition to a CNS disorder
is an association of type 1 diabetes (T1D) or Juvenile diabetes to Alzheimer’s disease
(AD). Research showed continuous insulin-deficient diabetes significantly reduced the
insulin signaling pathway activity by reducing insulin-degrading enzyme protein
expression and promoted AD behaviors.3 Moreover, the research showed that TransActivator of Transcription (Tat) protein and gp 120 of human immunodeficiency virus
(HIV) deacidify the endolysosome, which is normally acidic, and this can cause an
increased deposit of amyloid β-peptides (Aβ), thus resulting in Alzheimer’s disease. In
addition, the research has shown that a use of certain addictive substances make one
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more susceptible for HIV infection due to biochemical reactions induced by the addictive
substances.4
A direct association of a health condition to a CNS disorder is mainly due to
prolonged use of certain medications causing CNS disorders. Barreas et al. reported an
association between tumor necrosis factor-alpha inhibitors (TNFα-I) and demyelinating
diseases, a condition involving damage to the myelin sheath and this results in slowed
or stopped nerve impulses. TNFα-I is a biological agent used for a treatment of
rheumatology disorders and research has shown that the prolonged use of TNFα-I can
lead to demyelinating diseases.5 Furthermore, statistically, a majority of marketed CNSactive molecules are basic, and the pKa thereof fall into a range of 7.5 to 10.5.6 As
mentioned above, CNS disorders are chronic disorders and thus the patients have to
regularly take medications for a prolonged period of time, if not forever, in order to
control the symptoms. Hence, controlling CNS conditions using medications can also
deacidify endolysosomes resulting in AD for the patients.
Despite the complexity of diseases, with advancing science, more details
regarding CNS disorders are being elucidated. Society is becoming more aware of and
exhibits more understanding towards certain CNS disorders. Societal recognition is
typically delayed and this is particularly true especially in regards to CNS disorders. This
is because, while some conditions such as seizures are very obvious to others, many
CNS disorders are not prominent to others until the symptoms worsen. Moreover, even
in the medical field, the means to measure the degree of the symptoms have not been
established for a long time. Hence, many CNS disorders, including ADHD and
depression, have been arousing controversy and the conditions were not recognized as
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a health problem, but were rather dealt as individual differences or defects of moral
control. As a matter of fact, although the first case of ADHD was reported by Sir
Alexander Crichton in 1798, the societal recognition of ADHD was not established until
late 1990s.7
Societal recognition, as well as the availability of diagnostic technologies are very
important for patients, especially for those with invisible symptoms, in order to receive
the appropriate support and benefits. However, the awareness of CNS disorders is,
indeed, greatly promoting the number of patients diagnosed with CNS disorder(s) every
year. Figure 1.1. shows statistical data in 2013 as an example. There were 63.3 million
patients diagnosed with a mental disorder, 9.0 million with ADHD, 5.4 million with AD
and 2.8 million with epilepsy.8

Figure 1.1. The Number of New Patients in the U.S. in 2013.8

ADHD = Attention Deficit Hyperactivity Disorder, CLRD = Chronic Lower Respiratory
Disease
4

In addition, due to the lack of cures for CNS disorders, once diagnosed with a
CNS disorder, a patient will have the condition for the rest of one’s life. However, for
better or for worse, CNS disorders are generally not direct causes of death (Figure 1.2.).
Thus, unlike other fatal conditions, such as cancers, the CNS disorder patients would
likely live a normal lifespan. Even though AD is ranked among the highest health
causes of death in the United States from 2004 to 2014, AD is usually not the direct
cause of death. Except for rare cases (up to 5%) of early-onset AD typically affects
people older than 65. Thus, the death rate of AD patients is affected by death
associated with aging. Furthermore, AD patients often encounter difficulties to
adequately treat curable conditions such as infections due to dementia and/or other
symptoms related to AD, and the additional conditions can be the direct cause of death.
Likewise, depression associated suicides or other accidental death due to the physical
and/or mental limitations actuated by CNS disorders are not considered as death by
CNS disorders. Consequently, the total number of CNS disorder patients are drastically
increasing every year.
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Figure 1.2. Age-adjusted death rates for selected causes of death for all ages, by sex:
United States, 2004-2014.8

CLRD = Chronic Lower Respiratory Disease

Despite the increasing population of CNS patients, there are not enough
medications available, and a considerable percentage of patients have symptoms that
are not controlled by existing treatments or are suffering from severe side effects.
According to the FDA, there were 21 oncology drugs, 9 cardiovascular drugs and 9
respiratory diseases drugs approved in 2015, but there were only 6 neurology drugs
approved in the same year (Figure 1.3.). 9 This number is fairly low, especially given the
variety of CNS disorders and the population of the patients thereof.
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Figure 1.3. The Number of Drugs Approved by the FDA in 2015.9

The significant lack of CNS active drugs is a consequence of the discovery of
CNS active drugs not advancing fast enough due to multiple obstacles. First, although
the details will be discussed in the succeeding chapters, CNS disorders have very
complex pathologies and there are physicochemical limitations for the blood brain
barrier (BBB) permeability. This makes designing CNS active compounds profoundly
challenging. Thereafter, there can be synthetic difficulties and stability issues associated
with the designed compound. In addition, the designed molecules have to successfully
show the claimed efficacy with an acceptable degree of toxicity in in vivo and nonhuman in vitro, pre-clinical stage and clinical trials.
Figure 1.4. summarizes a comparison of CNS and non-CNS drugs in respect to
the FDA approval duration and rate.10 The statistical data inevitably shows that CNS
7

drugs require longer periods of time for the approval phase with a lower success rate
compared to that of non-CNS drugs. More specifically, from 1999 to 2013, the mean
approval phase length for CNS drugs was almost 5 months longer than that of other
drugs. In addition, from 1995 to 2007, while only 6.2% of CNS drug candidates which
entered Phase I testing were approved by the FDA, 13.3% of non-CNS drug candidates
were approved. That is, CNS drugs have less than half of the success rate in new drug
applications than all other drugs. The evaluation of CNS drugs takes longer because of
the complexity of pathology. Moreover, since the medication is intended to be
administered for a prolonged time, the determination of the end point is ambiguous,
considering the possibility of side effects and adverse toxicity inherent in continuous
use. In fact, there are drugs that were discontinued after a decade or longer, due to their
adverse side effects that arose with long-term use. However, of course, it is not realistic
to operate a clinical trial for over decades. Thus, clinical trials of CNS drugs tend to
require longer than that of non-CNS drugs. Even though both approval phase length
and success rate discrepancies have been substantially narrowed in the recent few
years, the challenges related to successful development and the FDA approval of CNS
drug is persistent.
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Figure 1.4. The FDA Approval Duration and Rate: CNS vs. non-CNS Drugs.10

NDA = new drug application, BLA = biological license application, Sub = submission,
App = Approval.

Accordingly, patients with CNS conditions not controlled with existing drugs or
with severe side effects are suffering for a considerably long time. In 2012, the World
Health Organization (WHO) reported the disability-adjusted life year (DALY) of patients
with CNS disorders (Figure 1.5.).11 The DALY was first developed in the 1990s to
analyze the overall health and life expectancy throughout the world, and is a parameter
to evaluate the overall disease burden for medical conditions. The burden is reported as
the number of years lost due to ill-health, disability or early death. The disease category
with the highest DALY, of course, is neurological disorders. Given the fact that CNS
disorders are seldom causes of early death, the majority of factors increasing the DALY
of CNS disorder patients are ill-health and disability. It is also noteworthy that HIV/AIDS
is the disease with the second highest DALY. As for the examples given earlier, there
are many cases of HIV-associated complications. Thus, those HIV patients are prone to
CNS disorders as well.
9

Figure 1.5. Percentage of Total Disability-Adjusted Life Years (DALYs) Lost from
Diseases.11

AIDS = acquired immune deficiency syndrome

As has been noted, although CNS disorders are becoming one of the major
societal problems, adequate solutions are not available. Provided the statistical data for
NDA success rates and the adverse climate for the development of CNS-active drugs,
CNS research is less likely to provide a satisfactory cost performance. However, other
data also shows the absolute need for more CNS research. Hence, we are highly
interested in developing new molecular entities (NME) for various CNS disorders,
particularly focusing on addiction, epilepsy and Parkinson’s disease. In the following
sections, descriptions of said CNS disorders is introduced.
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1.2.

Addiction

Addiction is a type of mental disorder which displays a compulsive engagement
for rewarding stimuli. Millions of Americans suffer from some form of addiction. In spite
of controversy among medical professionals, addiction generally is a very diverse
disorder, and the addictive stimuli are not limited to physical substances but also
behavioral elements. Thus, addiction is comprised of alcoholism, drug addiction, bulimia
and anorexia (eating disorders), gambling addiction, shopaholic behavior, workaholic
behavior, kleptomania (compulsive stealing), Internet/social media addiction and more.
While some addictive materials (e.g. tobacco, alcohol, etc.) or behaviors (shopping,
eating, etc.) are legal and are socially accepted, some others are illicit due to their
strong addictiveness and/or adverse effects to self or to others. Hereafter, we focus on
addictive substances that directly bind to CNS receptors and transporters to facilitate
neurotransmissions, rather than indirect addiction wherein a certain behavior results in
stimulation of neurotransmissions.
Intoxication impairs one’s judgment, physical abilities and health. Addiction
patients often commit crimes, in order to acquire the substances of interest which are
often illegal and sold at high prices. Even for legal substances such as alcohol and
tobacco products, a heavy tax is levied on them and they are not always affordable
especially for those who have lost productivity and/or are unemployed due to addiction.
Accordingly, the NIH reported that the annual cost of law enforcement, lost work
productivity and healthcare related to substance abuse to the U.S. is more than $700
11

billion.12 The National Survey on Drug Use and Health (NSDUH), estimates about 8.7%
of Americans aged 12 or older, which is roughly 21.8 million people, were active illegal
drug users in 2009, and statistically the number is increasing.13 Among all age groups,
young adults (age 18 to 25) are the largest age group of illegal drug users, and the
effect of this usage indubitably raises concerns on the nation’s economy, crime rate and
public health for the near future. In addition, addiction in even younger ages certainly
affects the development of brain and causes learning disabilities.14 According to a report
released by the Department of Justice, National Drug Intelligence Center, the amount of
illicit drugs coming into the U.S. from all over the world is also, unfortunately,
increasing.13
Besides the direct impairment effects from addictive substances and death
caused by overdose, there are other health effects that can ultimately be fatal. HIV
infection is a representative example because it is tightly related to various substance
addictions, and is one of the biggest health issues worldwide. One of the severe effects
of some addictive substance is a disruption of the BBB. Research has shown that
cocaine and alcohol can alter the BBB permeability and allow foreign substances to
pass through the barrier.15, 16 Consequently, cocaine or alcohol abusers become more
prone to brain infection, including neuroHIV. Cocaine also affects the upregulation of CC chemokine receptor type 5 (CCR5). CCR5 is one of the major receptors that the most
widespread type of HIV, HIV-1, uses to enter immunological host cells, and therefore,
compromised CCR5 enhances HIV infectivity.17 Likewise, methamphetamine-abusing
HIV patients exhibit intensified neurocognitive impairment and a higher degree of
addiction. Furthermore, methamphetamine destroys the neurons and mitochondria of

12

astrocytes, and causes dopamine levels to collapse.15 Dopaminergic functions are not
only related to addiction but also to immunological competency of the CNS.18 Moreover,
although it has been a controversy whether or not marijuana (cannabis) is addictive,
some researchers believe cannabis is addictive and have observed the correlation of a
suppressed immune system with cannabis abuse.19
Addiction can be treated in several ways, including detoxification, behavioral
counseling, and medication. Medications are available for substance abuse or mental
disorder associated addiction. To control dopaminergic addiction, the drugs have to
reregulate dopamine levels, for example, by antagonizing the Dopamine 3 (D3)
receptor. In addition to dopaminergic synapses, glutamatergic synapses are involved in
addictions. Accordingly, the following are the examples of drug classes available in the
market for specific targets in addictions: metabotropic glutamate receptors (mGluR) 2
and 3 agonists, mGluR5 negative allosteric modulators (NAMs), α-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, N-methyl D-aspartate
(NMDA) partial antagonists, glutamate transporter 1 (GLT1) modulators, and cysteineglutamate exchanger modulators.20 Nonetheless, these are merely examples and there
are addiction patients with unknown etiologies, very often, with combinations of multiple
pathologies and a single medication does not adequately control the symptoms.
Considering the growing population and adverse effects on the society, addiction
is a major public health problem. However, due to the wide variety and complexity of
mechanisms, there are not enough treatments for those patients. Therefore, new
treatments for addictions are perpetually in high needs.
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1.3.

Epilepsy

Epilepsy, also known as seizure disorders, are disorders defined with symptoms
involving unpredictable and repeated seizures caused by malfunctioning nerve cell
activity in the brain. Epilepsy affects about 3 million people in the U.S. and is ranked as
the fourth most common neurological disorder.21 Globally, the WHO estimates 50 million
patients, of which nearly 80% of them live in low to middle income counties.11 Even
though seizures are often considered as uncontrollable shaking movements of the arms
and legs, there are various types of seizures, including loss of consciousness and
awareness, a staring spell, temporary confusion and psychic symptoms. The symptoms,
degree and frequency of seizures vary by individuals. In the medical field, seizures are
comprised of focal seizures and generalized seizures.
Focal seizures are further comprised of simple partial seizures and complex
partial seizures. Simple partial seizures are focal seizures without loss of
consciousness, and even though they may involve emotional or sensory changes, the
patients are aware throughout the event. Complex partial seizures, on the other hand,
are focal dyscognitive seizures, and involve altered mental status, or loss of
consciousness or awareness. That is, in some cases, the patients do not faint but
become unresponsive while staring at one point or engage in particular repetitive
actions such as walking in circles or rubbing a single place of the body. Since focal
seizures do not necessarily involve typical jerking arms or legs, they are sometimes
confused with other CNS disorders, especially mental illness. Therefore, the symptoms
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must be monitored thoroughly and adequately, and thus, the diagnosis of focal seizures
may be delayed and proper treatments may not be provided immediately. Focal
seizures occur due to an abnormal activity of a single area of the brain. Therefore, it is
rather feasible to control focal seizures.22
In contrast, more complex cases are generalized seizures, which involve all
areas of the brain. Generalized seizures are further comprised of clonic seizures,
myoclonic seizures, tonic seizures, tonic-clonic seizures, atonic seizures and absence
seizures. Clonic seizures are the characteristic movements of jerking muscles on the
arms, face, and neck. In a similar manner, myoclonic seizures involve jerks or twitches
of the arms or legs, but the event is much shorter than clonic seizures. On the other
hand, tonic seizures are caused by stiffened muscles, and thus, often cause the patient
to collapse especially when they affect the core muscles. Tonic-clonic seizures are the
most extreme symptoms among all the epilepsy cases. As they sound, tonic-clonic
seizures are combinations of the two types of seizures and more, and the symptom
involves a sudden loss of consciousness, the simultaneous muscle stiffening and
jerking, and in some severe cases, loss of bladder control. Tonic-clonic seizures used to
be called grand mal seizures. Similar to tonic seizures, atonic seizures also involve the
outcome of abrupt collapses, but the collapses are due to a loss of muscle control
instead of stiffness of muscles. Atonic seizures are also called drop seizures. Lastly,
absence seizures are common among children and, therefore, are also called petit mal
seizures. The symptoms involve staring into space and eye blinking or lip smacking with
a brief loss of awareness. Absence seizure can occur repeatedly in a short time
period.22
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As the symptoms vary by individuals, epilepsy can be caused by a number of
factors. The statistics show that more than half of all epilepsies are caused by either
stroke, head trauma, brain tumors or brain infections. A partial disruption of brain cells
due to stroke can affect brain function, and thus, can cause seizures. Head trauma or
injuries are physical disruption of the brain, and similar to stroke, can lead to permanent
damage in the brain, which causes seizures. Moreover, brain tumors also interrupt
normal function of the brain, and may cause seizures. Brain infection, as described in
the previous section, can significantly alter brain function. Hence, brain infections such
as HIV and viral encephalitis can also be a cause of seizures. The research show an
implication of correlation between autism and epilepsy.23 However, there are
controversies and this hypothesis is not fully validated because, as explained above,
symptoms of neurodevelopmental disorders and focal seizures can be similar and
difficult to distinguish from one to another. In addition, genetic factors seemingly affect
one’s likelihood of having epilepsy.24 Furthermore, even though epilepsy can affect all
ages, statistical data shows that more children and elder adults (age over 60) are more
susceptible to seizures.25 Despite the differences in symptoms, gender is unlikely the
cause or risk factor of epilepsy.26 Yet, 6 out of 10 epilepsy patients have seizures with
unknown cause, making the determination of appropriate treatments challenging.21
Epilepsy can be diagnosed in multiple ways. Based on general examinations,
including inquiry and observations of the symptoms, doctors decide additional
diagnostic techniques and treatments suitable for the specific case. When the cause is
physical damage or abnormality of the brain, such as tumors or infections, epilepsy can
be diagnosed through blood tests and a computed tomography (CT) scan. If the cause
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is not identified with the said techniques, but the patient still displays epileptic
symptoms, the following techniques are employed to identify more details. Similar to a
CT scan, a magnetic resonance imaging (MRI) and a functional MRI (fMRI) are often
employed. MRI shows the area of the brain affected and possibly some abnormalities,
such as a tumor, causing the seizure. fMRI shows the blood flow in the brain and helps
to understand the area possibly involved in the seizure and/or the area dictating the
basal function, and thus the area to avoid during surgery. Other techniques used are a
positron emission tomography (PET) scan and an electroencephalogram (EEG), and
those allow doctors to visualize the electrical activity of the brain and the specific
locations thereof. EEG, especially, is commonly used nowadays because abnormal
electrical activity can be detected even at the moment the patient is not having a
seizure. In addition, unlike PET scan, EEG does not require radioactive material to be
administered, but is external and uses electrodes on the scalp, it is considered a safer
method of diagnostics.22
In accordance to the diagnoses, appropriate treatments are chosen from antiepileptic drugs (AEDs), surgeries or other therapies including dietary restrictions. The
AEDs are classified into three categories based on the pharmacokinetics displayed:
those acting on single neurons, those acting on local network of neurons, and those
acting remotely to limit excitation and seizure spread. The treatments at the single
neuron level target intracellular ion-activated potassium currents, transmembrane ion
gradients, membrane shunting, and energy failure. The treatments at the local network
of neurons target glutamate depletion, the intra- and extracellular environments, Glial
buffering of glutamate, gap junctions, increased GABAergic inhibition, and
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neuromodulators (e.g. endocannabinoids, adenosine, and neuropeptide Y). The
treatments acting remotely, target vagal nerve stimulations (VNS), and subcortical brain
regions such as GABA receptors.27
However, as said before, more than half of epilepsy patients have seizures with
unknown mechanisms and thus selecting an appropriate AED(s) for those patients is
not straightforward. Furthermore, even for those who have medications that work for
their particular case, many suffer from moderate to severe side effects. For example,
the side effect of AEDs on bones has been a major problem for over 50 years. The
research has indicated that prolonged use of AEDs alters bone metabolism as seen in
the following parameters. According to the data, in the serum of the patents, who
regularly use AEDs, reduced calcium, phosphate and Vitamin D, and elevated
parathyroid hormone, markers of bone formation and markers of bone resorption were
found. As a result, AED users have significantly decreased bone density and higher risk
for other bone diseases.28
In addition, especially in the case of genetically caused epilepsy, correlations
between epilepsy and other CNS disorders are reported. Fassio et al. identified that
mutation in Synapsin 1, phosphoproteins encoded by the SYN1 gene in humans,
causes epilepsy and autism spectrum disorders (ASDs).23 Wong and Guo summarized
the literature and concluded that a genetic defect on trisomy 21 causes epilepsy and
Down’s syndrome, protein synthesis regulated by tuberous sclerosis complex (TSC)
genes causes epilepsy and tuberous sclerosis, fragile X mental retardation 1 (FMR1)
triplet causes epilepsy and fragile X syndrome, and methyl CpG binding protein 2
(MECP2) gene repressor causes epilepsy and Rett syndrome.29
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Hence, the side effects of existing AEDs and epilepsy associated complications,
including the examples above, make epilepsy treatment more complex and sometimes
unfeasible. Although each seizure usually lasts only a few minutes with the longest case
being reported at 11 min,30 the occurrence thereof is unpredictable and can greatly
affect the quality of life. Moreover, about one-third of patients still have seizures that are
not controlled due to unavailability of the correct medication for their epilepsy. 21
Therefore, the need for new AEDs is urgent and more rapid research is absolutely
required.

1.4.

Parkinson’s Disease

Parkinson’s disease (PD) is a chronic and progressive movement disorder which
mainly involves the malfunction and death of neurons. PD was named after James
Parkinson who first described symptoms called “paralysis agitans” in 1817, which was
later renamed Parkinson’s disease.31 PD is the second most common
neurodegenerative disorder after AD, and the number of patients in the U.S. is
estimated to be up to a million and to over 10 million worldwide. The cost of PD in the
U.S., such as medical costs, social security payments and lost income from inability to
work due to the condition, are about $25 billion per year.32
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PD is most recognized as motor symptoms including resting tremors,
bradykinesia, rigidity and postural instability.32 Not all, but about 70% of PD patients
develop tremors, usually one of the first symptoms. Tremors are an involuntary muscle
contraction and relaxation, consisting essentially of twitching/shaking or oscillating
movements of one or more body parts. For PD patients, tremors occur when the muscle
is relaxed and thus it is called resting tremor. Bradykinesia is characterized by slowness
of movement and affects not the initiation, but the execution, of movements.
Bradykinesia directly disturbs performance of daily functions and the ability to work.
Bradykinesia can also affect patients’ ability to communicate with others by slowing
muscles for speech and facial expression. Rigidity affects the flexibleness of muscles
mainly in the legs, shoulders and neck. When rigidity involves pain, or is associated with
bradykinesia, the mobility of the patient is significantly limited and affects the ability to
practice a quality life. Postural instability is a balance problem that influence patients’
ability to stand and stay upright. Inability to keep an upright posture can cause collapse
and may result in a serious injury.
In addition to motor symptoms, there are secondary motor symptoms and nonmotor symptoms. Secondary motor symptoms include unwanted accelerations,
micrographia, and freezing of gait (FOG). Unwanted accelerations are very interesting
because, although typical symptoms of PD are slow movements as mentioned before,
the opposite symptoms are also observed in certain cases. Unwanted accelerations
include not only physical movements but also speech. The uncontrollably fast
movement may cause collapse or other physical injury, and excessively fast speech
(tachyphemia) may affect communication. Micrographia is a condition where
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handwriting becomes abnormally small or cramped. This symptom is often seen before
other cognitive symptoms.33 FOG is one of the most common Parkinsonian gaits and is
typically a transient episode. The typical FOG is hesitation of the start of walking in
which the patients are unable to start walking despite their intention to do so. FOG can
also occur upon the intention of turning, or passing through a narrow or tight place such
as a doorway.34 Triggers of FOG vary, but each case can include reaching a destination
and unexpected sounds such as doorbell rings. Like other symptoms associated with
PD, FOG occurs contrary to patients’ intention and anticipation, FOG may also cause
an individual to fall down. Non-motor symptoms usually appear prior to full development
of PD with motor symptoms and, as it is named, do not involve movements or physical
impairments. For example, preceding the occurrence of motor symptoms, some patients
display symptoms such as loss of sense of smell and orthostatic hypotension.
In addition to the symptoms, as with other CNS disorders, there are PD
associated complications. For example, many PD patients experience sleep disorders
such as REM sleep behavior disorder (RBD). For healthy sleep, the muscles are
temporary paralyzed and rest the body during REM sleep. However, RBD patients lack
this temporary muscle paralysis during REM sleep and get physically agitated. As a
result, patients may walk, move their limbs and talk or scream while sleeping. During
the episode, since they are asleep, they are unconscious and do not remember the
event. However, the symptoms may be quite violent and can cause injury of themselves
or others.35 In fact, RBD is now well-known for its association to PD, and some experts
believe that RBD is one of the first symptoms of neurodegenerative diseases, including
PD. The data shows that prevalence of RBD among PD patients is 30 to 41%, and 18 to
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25% of PD patients displayed symptoms of RBD, 3 to 4 years prior to the onset of PD.36
In a similar manner, depression is a very common CNS disorder among PD patients.
The prevalence of depression in PD is estimated to be 20 to 45%.37 Diagnosis of
depression in PD is rather difficult as the two disorders have overlapping symptoms.
However, similar to RBD, the study shows that depression often occurs preceding to
onset of motor symptoms of PD. Furthermore, the statistics show that 78% of PD
patients are suffering from visual dysfunction, such as double vision, disordered color
recognition, or misjudged object perception.38, 39 The simultaneous occurrence of motor
symptoms of PD and visual dysfunction can be critical for patients to achieve daily
functions.
In spite of decades of dedicated research, the cause of PD remains unknown.
However, statistical data implies that there are several risk factors mainly categorized in
genetic factors, environmental factors, epigenetic factors and combinations thereof.
Specific genes identified in relation with PD thus far are autosomal-dominant PD genes,
such as SNCA, LRRK2 and VPS35, and autosomal-recessive PD genes, such as
Parkin, DJ-1, PINK1 and DNAJC6. Researchers are actively trying to identify other
genes associated with PD and the likelihood thereof. Environmental factors include, but
are not limited to, exposure to harmful substances, such as alcohol, pesticides, and
tobacco, and more physical and direct factors such as injury to the brain. Epigenetic
factors are those which are nongenetic factors that influence or alter genetic
expressions. For example, DNA methylation alters gene expression by influencing the
binding affinity of the sequence to a particular protein.40 Age is also one of the factors,
and only about 4% of the patients with PD were diagnosed before the age of 50. At age
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60, PD affects over 1% of the population and the prevalence increases up to about 4%
at the age of 80.41
Diagnoses of PD is particularly difficult and there is no test or examination
available to give adequate information to diagnose PD. Although some imaging
techniques, such as PET, can be employed in order to identify the existence of other
neurological disorders, PD cannot be visualized with those techniques. Hence, the
diagnoses are mainly executed based on observation of behavioral symptoms and
family history. The diagnoses of PD, therefore, may take years until a conclusion comes
and adequate and appropriate treatments may not be provided in a timely manner. 32
As PD is a chronic and progressive disorder, there is essentially no cure or
medication for improving the symptoms. The treatments available include surgery,
rehabilitation, restoratives, and medications, but these options merely slow down the
progression of the disease. Surgeries that help to control PD are destruction of lesion
region (e.g. pallidotomy) and deep brain stimulation (e.g. thalamus). Restorative
methods utilize direct replacement or alterations such as transplantation and stem cell
utilization. Rehabilitative measures include physical therapy, occupational therapy and
speech therapy. PD medications are classified into two categories based on the target
of action: dopaminergic and nondopaminergic medications. Among all the available
treatments, the most common and effective one is dopaminergic medications, though
the patients still suffer from side effects and long-term drug resistance and the cost of
medications is high.42
Although more effective options are available for PD as compared to other
neurodegenerative disorders, such as AD, no existing medications or other treatments
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have adequate efficacy with acceptable side effects, especially for a long-term use. As
motor symptoms of PD affect the ability of patients to carry out daily tasks, PD patients
often require uninterrupted professional care. The combined cost of medications and
care, puts a financial burden on patients and families in addition to the loss of income
due to inability of the patient to work because of the condition. Hence, the development
of improved PD medications is essential.

1.5.

CNS-Active Drugs

CNS drugs are mainly classified as either stimulants, depressants, or
hallucinogens, based on their activities. In order to achieve an efficacy with minimal side
effects, a drug has not only to target a specific system but also to perform in desired
manner (i.e. agonist or antagonist). Unlike oncology or antibacterial drugs, CNS drugs
cannot be a suicide inhibitor or enable a certain system. Instead, the drugs have to
regulate the target system by either enhancing or suppressing the system to a suitable
extent.43 The details of the different classes and examples of CNS active drugs are
discussed subsequently.
Stimulants are type of CNS drugs that accelerate or enhance targeted
neurotransmissions. For example, illicit drugs such as ecstasy, cocaine and
methamphetamine are neurostimulants. Other addictive, yet legal substances, such as
nicotine and caffeine, are also neurostimulants. For medicinal use, stimulants are
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employed for many CNS disorders, including as antidepressants and anti-ADHDs. In
fact, methamphetamine 1 was originally developed and approved by the FDA for ADHD
and obesity treatments.44 However, because of the recreational effects and adverse
side effects, methamphetamine is rarely prescribed even for the initial purpose. An
overdose of methamphetamine can cause death. Also, caffeine 2 is used for one of the
active ingredients of pain medications. Methylphenidate 3 is a FDA approved drug,
which is used for treatment of ADHD and narcolepsy. Despite its efficacy,
methylphenidate is also known as an addictive prescription drug, and overdose can
cause overstimulation of CNS. The side effects include minor symptoms, such as
headache, twitching and vomiting, to adverse symptoms, such as coma, hyperpyrexia
and circulatory collapse (Figure 1.6).45

Figure 1.6. Structures of Methamphetamine, Caffeine and Methylphenidate.

Another noteworthy stimulant is L-DOPA (L-3,4-dihydroxyphenylalanine) 5, which
is one of the most efficacious medications for Parkinson’s disease. L-DOPA is a
precursor of dopamine and is a dopamine agonist. L-DOPA is synthesized from L25

tyrosine 4 by the enzyme tyrosine hydroxylase and converted to dopamine 6 with the
aromatic L-amino acid decarboxylase (AADC) in biosynthetic pathways in the brain
(Scheme 1.1.). L-DOPA was first introduced by Arvid Carlsson as a treatment of PD in a
report published in 1957,46 and is still used as such after 60 years. Carlsson received a
Nobel Prize in 2000 for this work. Anti-parkinsonian medications, however, have mainly
three objectives: 1). to halt disease progression, 2). to improve motor and non-motor
symptoms of PD and 3). to minimize the side effects.42 L-DOPA is very successful, in
terms of suppression of symptoms at the early stage. However, as the disease
progresses, L-DOPA is not sufficient to control all the symptoms. In addition, as LDOPA cannot halt or reduce progression of the disease it is not an adequate treatment
of PD over the long-term. Moreover, like other dopaminergic transmission, L-DOPA
usage is associated with side effects such as hypotension, vomiting, cardiovascular
dysfunction and mental dysfunction.47 About 40 to 50 % of PD patients acquire motor
complications after 5 years of L-DOPA treatments.48

Scheme 1.1. Biosynthesis of L-DOPA.
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On the other hand, depressants slow down or suppress targeted
neurotransmissions, and are also known as relaxants. It must be clarified that
depressants cause CNS depression, but are not principles or causes of depression, as
a disorder. Illicit or controlled depressants include heroin, cannabis, and morphine.
Alcohol is a commonly used legal depressant. For medicinal uses, depressants are
used for the treatment of epilepsy, addiction, depression, anxiety, pain and insomnia.
Morphine is clinically used to reduce both acute and chronic pain. Although it is a
subject of controversy, cannabis is a medically used depressant for many treatments
including nausea and vomiting associated with chemotherapy, chronic pain, epilepsy,
stress/anxiety disorders, sleep disorders, neurodegenerative diseases, multiple
sclerosis, or as an appetite stimulant for HIV/AIDS patients.49 There are two active
compounds, tetrahydrocannabinol (THC) 7 and cannabidiol (CBD) 8, in cannabis
(Figure 1.7.). THC is the psychoactive ingredient associated with the “high” feeling and
CBD is the non-psychoactive ingredient. It is believed that THC plays the main role for
the efficacies of the most of aforementioned applications.50 Hence, medicinal cannabis
cannot be modified to contain only CBD, and thus we are unable to eradicate the
addictive and recreational aspect of it.
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Figure 1.7. Structures of Tetrahydrocannabinol and Cannabidiol.

Another class of well-known depressants is the benzodiazepines (BDZ). BDZs
are used for a wide range of CNS disorders, such as bipolar disorder, epilepsy, panic
disorder, insomnia, addiction, and schizophrenia. The general structure of BDZs
consists of a 7-membered ring (1,4-diazepine), fused with a benzene ring and another
benzene ring branched out of C5 of the 1,4-diazepine ring 9 (Figure 1.8.).
Chlordiazepoxide was the first clinically used BDZ and was discovered by Leo
Sternbach in a course of developing new psychopharmacological compounds. 51 The
interesting story is that he synthesized about 40 benzoxadiazepines in 1930s but all
compounds were inactive in biological testing. Since they were chemically unstable,
Sternbach made modifications to stabilize those compounds for storage and left them
on the shelf. As he was cleaning up his lab decades later, he decided to test those
analogs for pharmaceutical evaluation, and discovered one of them has an activity
similar to meprobamate. Meprobamate is a derivative of carbamate and used for
treatment of seizures targeting γ-aminobutyric acid A (GABAA) receptors.52 The first
clinical use of benzodiazepine was in 1960 as an anti-anxiety drug, which was a major
breakthrough in CNS drug discovery. Although BDZs have been commonly used ever
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since, there are severe side effects and BDZs are controlled substances in the U.S. due
to addictiveness thereof. The number of deaths from overdosing on BDZs are drastically
increasing since 2000 and 3.8% of all overdose deaths are from BDZs.53 The common
side effects of BDZs include drowsiness, dizziness and lack of coordination. In addition,
long-term use of BDZs may worsen psychiatric symptoms such as depression and
anxiety disorders, and recent research indicates that perpetual use of BDZs may cause
decrease in the spine density of pyramidal neurons.54 This may cause altered synaptic
connectivity and lead to CNS disorders such as schizophrenia.55

Figure 1.8. General Structure of Benzodiazepine.

Hallucinogens are substances that alter perceptions and states of consciousness
of users, and produce hallucinations as a result. In other words, hallucinogens often
cause people to see things, colors, events and such that do not actually exist. The
efficacy varies greatly by individuals, and the degree of the effect is generally
unpredictable. The examples of hallucinogens are lysergic acid diethylamide (LSD),
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psilocybin which is known as the psychoactive substance of magic mushrooms, and
ketamine. Hallucinogens have been used for over centuries in religious rituals and
recreationally.56 For medicinal use, hallucinogens are usually used to treat addictions,
though hallucinogens can be addictive as well, and are associated with adverse side
effects.
Nonetheless, the medicinal interest of hallucinogens arose in the late 1800s
along with discovery of mescaline and the effects if this compound. 57-58 The clinical
research on hallucinogens accelerated around 1950s through discovery of LSD and
psilocybin by Hofmann et al.59-61 The research was aggressively active until around the
1970s when hallucinogens were classified as the highly restrictive Schedule I class
substance by The Controlled Substance Act (21 U.S.C. § 812), and researchers
concluded that the concern of hallucinogen abuse is greater than their clinical value.
Although in recent years, some researchers are attempting to revive hallucinogens for
treatment of alcohol and drug addiction, the risk of side effects is still present, and no
evidence exists to suggest significantly better efficacy compared to other available
addiction treatments.
Existing CNS active drugs are associated with moderate to severe side effects,
and the prescription of such compounds must be done carefully. Moreover, despite the
fact that the majority of CNS disorder patients require consistent treatments, the longtime use of CNS drugs induces reduced efficacy and/or additional health problems due
to side effects.
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1.6.

Summary

In summary, the population of CNS disorder patients are drastically increasing
because of awareness of the diseases as well as the stress of complex modern society.
Therefore, CNS disorders have become major societal problems especially in terms of
social health and financial loss due to the disorders. However, the treatments available
for CNS patients are not adequate and many patients have conditions that are not
controlled by existing medications, greatly affecting their quality of life and limiting their
competency. Furthermore, some patients do not have access to the appropriate
medications due to their high cost. Therefore, development of new CNS drugs is highly
needed.
Focusing mainly on addiction, epilepsy and Parkinson’s disease, the objectives
of this project were: 1). to improve the yield of p-methoxy-benzylidenation of D-glucal in
the formation of the lead compound 12 (Figure 2.3.), which has shown antiepileptic and
anti-chronic and acute pain effects (details shall be discussed in Chapter 2), 2). to
further develop a novel carbohydrate template and synthesize its derivatives for
potential CNS-active drugs (Scheme 2.6.), and 3). to test biological activities of the
derivatives prepared to evaluate their potential for therapeutic uses for the treatment of
various CNS disorders.
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Chapter 2

Synthesis of A Novel Carbohydrate Template and Its Analogs for the
Treatment of Addiction, Epilepsy, Parkinson’s Disease and other CNS
Disorders

2.1.

Introduction

Despite perpetual increases in the number of CNS disorder patients, there are
not enough treatments available on the market and not enough research is actively
being done to discover new compounds. The reason for that is, besides the burden of
the new drug application (NDA) approval and the cost performance of development of
CNS-active molecules as discussed in the preceding chapter, it is also very difficult to
design CNS-active molecules from a chemistry perspective.62 The major challenges
involve overcoming the blood brain barrier (BBB), in order to exhibit the desired efficacy.
The BBB is a very selective, permeable system between the blood and the brain
extracellular fluid and prevents passage of substances from the blood stream to the
brain.63 In other words, the BBB is a protective system of our brain from pathogens and,
therefore, brain infections are very rare. However, because pharmaceutical molecules
are foreign substances they can also get rejected by the BBB. Thus, CNS-active
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compounds have to be designed in such a way as to pass through the BBB while
keeping the desired selective binding affinity to specific receptor(s) of interest.

Figure 2.1. Components of the Blood Brain Barrier.64

The BBB, however, also has several mechanisms of intermembrane molecular
transportation (Figure 2.1.). The paracellular aqueous pathway, which is extremely rare,
passes hydrophilic small molecules through endothelial tight junctions (TJ). The
transcellular lipophilic pathway allows passive diffusion of lipophilic molecules through
the lipid layers of the membrane. Transport proteins are highly specific molecular
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transporters, that include the glucose transporters (GLUTS). Some macromolecules can
also be selectively transported via receptor-mediated transcytosis or adsorptivemediated transcytosis.
In 2001, Lipinski et al. published a report categorizing solubility and permeability
characteristics of drugs,65 which further led to what is known, the Lipinski “Rule-of-five”,
published in 2004.66 The Rule of five is formulated based on a number of orally
administered drugs and is used for an evaluation of the likelihood of a drug candidate
being bioavailable following oral administration. Pointedly, the Rule of five defines
molecules’ bioavailability potential based on their size and liphophilicity. More
specifically, the rule of five is as follows:
•

H-Bond Donors ≤ 5

•

H-Bond Acceptors ≤ 10

•

MW ≤ 500

•

logP ≤ 5.

Since the majority of CNS disorders are non-curable, the patients have to take
medications regularly to control their symptoms and oral administration is most
desirable and realistic without assistance from health professionals.
Furthermore, Pajouhesh et al. in their review paper summarized attributes of a
successful CNS agent based on marketed CNS-drugs.67 The criteria set forth are much
narrower than the Lipinski’s rule of five, taking into consideration metabolic stability,
metabolic liability, the BBB permeability, protein binding and hERG inhibition. Focusing
on the physicochemical properties, that mainly dictate the permeability, the following are
the attributes of a successful CNS-drugs:
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•

Molecular weight < 450

•

cLogP < 5

•

H-bond donor < 3

•

H-bond acceptor < 7

•

Rotatable bonds < 8

•

pKa 7.5-10.5

•

Total polar surface area (PSTA) < 60 – 70 Å2.

These factors can be obtained as well-simulated computational data. Although the
authors also specified enzymatic stability and other factors besides the abovementioned
criteria, those factors cannot be fully controlled at the time of molecular design because
they have to be determined experimentally.
Although, in recent years, nanomolecules have been employed as
pharmaceutical vehicles to overcome the BBB, carbohydrates alone are potentially
good candidates for CNS-drugs because they are likely to pass through the BBB,
without a vehicle, and act as a medicinal compound. First, carbohydrates are the most
abundant natural molecules and therefore they are available at a relatively lower cost.
Even though the final cost for the drug at the end user is not purely dependent on the
cost of ingredients, lower-cost starting materials can ultimately reduce the marketed
cost of the drug. On the other hand, use of polymeric nanomolecues for drug delivery
can be very costly and can greatly affect the affordability. Second, carbohydrates are
highly biocompatible. Especially in terms of overcoming the BBB, carbohydrates are
one of the best candidates. Aside from functions of carbohydrates in cells providing
skeleton-structure stabilities, cell recognition and other functions, carbohydrates are the
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main energy source for our body and are the only energy source of the brain. As briefly
mentioned above, glucose transporters (GLUTS) are a group of membrane proteins that
specifically transport glucose and other carbohydrate molecules through a membrane.
Hence, the GLUTS are expressed on the BBB and in neurons, and carbohydrate
molecules can utilize the GLUTS to target CNS receptors and transporters. In addition,
monosaccharides are ideal to design molecules to satisfy the attributions for successful
CNS-drugs as mentioned above. Monosaccharides are small in size and thus, in
addition to exploiting transporters, they can also pass the BBB through passive
diffusion. Moreover, there are many functionalizable sites in monosaccharides that can
be modified regio- and stereoselectively. Hence, they are suitable for designing
modifications for highly specific targets.
Despite the therapeutic value and beneficial properties of carbohydrates, there
are only a few dozen carbohydrate-based drugs approved by the FDA, which is a very
small number in comparison to the total number of FDA approved new molecular
entities of 1,453 in 2013.69 Moreover, there are more polysaccharide- or
oligosaccharide-based drugs than monosaccharide-based drugs.70 Besides epileptic
treatments with topiramate and 2-deoxy-D-glucose,71 to the best of our knowledge,
carbohydrates are not used for CNS-active drugs. The concerns associated with the
use of monosaccharide derivatives for CNS-active drugs are their target specificity and
enzymatic stability, as well as synthetic difficulties. The aforementioned regio- and
stereoselective modifications are feasible for carbohydrate molecules, yet, because of
the chemical similarities of hydroxyl groups, some modifications require multiple steps
involving chemoselective protection and deprotection, and/or result in diastereomers
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and other products. Though diastereomers are separable in theory, unlike enantiomers,
diastereomers of carbohydrate derivatives with bulky group(s) are often hard to
separate or are inseparable. Furthermore, carbohydrates are often temperature and
acid labile and thus the reaction conditions that can be used are limited. Likewise, as a
number of carbohydrates exist in the body and are metabolized, carbohydrate
derivatives are also likely to be susceptible to enzymatic degradation.
Nonetheless, we believe that it is worthwhile to investigate the potential of
monosaccharide derivatives as CNS-active compounds and thus this project has been
established.

2.2.

Background

In 2008, Marzabadi and Talisman developed and reported a series of novel
cyclopropanated carbohydrates targeting CNS disorders, especially bipolar disorder and
epilepsy.72 The idea behind the design of these molecules was to incorporate structural
features of both topiramate, an antiepileptic drug, and the benzopyrans, agonists for
mGluR’s, in order to develop better antiepileptic drugs. In Figure 2.2. the Markush
structures of the novel cyclopropanated carbohydrates that are patented by Marzabadi
and Talisman in 2012 are shown.73
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Figure 2.2. Markush Structures of Novel Cyclopropanated Carbohydrates.

Based upon data from biological studies, some of the derivatives prepared
showed the desired biological activities but not to the extent that was anticipated.
However, one of the precursors 12 (structure shown in Figure 2.3.) surprisingly
displayed remarkable biological activity. Compound 12 exhibited nanomolar affinities to
GABAA receptors as well as mGluR2 in vitro and showed sedation and weight gain in
vivo. Moreover, 12 also displayed anti-chronic and anti-inflammatory pain effects in vivo.

Figure 2.3. Structure of Lead Molecule 12.

Given the potential of the lead molecule 12, we were interested in further
modifying and expanding the library of derivatives to study their structure activity
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relationships (SARs) for CNS disorders. Our therapeutic targets were not limited to
epilepsy and bipolar disorder but also extended to the entirety of CNS disorders.

2.3. Results: Chemistry

Hereafter we describe attempted improvements in synthesis of 12, and the
syntheses of a series of carbohydrate analogs of the novel carbohydrate template
(Scheme 2.6.), developed for potential CNS-drugs.

Scheme 2.1. Syntheses of Tri-O-acetyl-D-glucal 15.

We started our syntheses from readily available α-D-glucose 13. The 1,2elimination of glucopyranose has been achieved via peracetylation of the sugar, then
anomeric bromination with HBr in acetic acid and acetic anhydride to form 14. This was
followed by elimination at the C1-C2 positions using zinc dust and sodium acetate,
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copper sulfate and acetic acid in water to form 3,4,6-tri-O-acetyl-D-glucal (TAG) 15, in
68% over 2 steps (Scheme 2.1.).74

Scheme 2.2. Synthesis of Compound 12.

The per-acetylated D-glucal 15 was deacetylated with sodium methoxide in
methanol to afford unprotected D-glucal 16 in a quantitative yield.75 D-glucal 16 then
underwent benzylidenation with p-anisaldehyde dimethylacetal and pyridinium ptoluenesulfonic acid to form compound 12. Unfortunately, the yield from the
benzylidenation of D-glucal was low. In fact, carbohydrate chemists have been
attempting to develop a better method but acetalization/ketalization of glycals is still
known to be a low yielding reactions nonetheless. In our attempts to improve yields, we
tried various acid and solvents. The acids included: p-toluenesulfonic acid (pTsOH),
pyridinium p-toluenesulfonic acid (ppTs), titanium tetrachloride (TiCl4), and trimethylsilyl
trifluoromethanesulfonate (TMSOTf), and the solvents used were N,Ndimethylformamide (DMF), tetrahydrofuran (THF), and acetonitrile (AcCN).
Unfortunately, the use of different acids or different solvents did not improve the yield
(Table 2.1.). Ma et al. reported 86% yield for benzylidenation of D-glucal using
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anisaldehyde diethylacetal.76 Since anisaldehyde diethylacetal is not readily available in
the U.S., we attempted in situ formation of anisaldehyde diethylacetal by employing
triethylorthoformate as a solvent or co-solvent with DMF using known literature
procedures.77, 78 However, no desired product was formed and we were unable to
reproduce the published results. Ultimately, the use of co-solvent (DMF-toluene)
afforded significantly better yield and the details thereof will be discussed.

Table 2.1. Various reaction conditions for solution based benzylidenation of D-glucal
with p-anisaldehyde dimethylacetal.

Solvent

Acid

Temperature

Yield

(0C)

(%)

Acid amount

DMF

pTsOH

0.01 equiv.

40

13

DMF

pTsOH

0.02 equiv.

40

13

DMF

pTsOH

0.1 equiv.

40

15

DMF

ppTs

0.1 equiv.

40

14

DMF

TiCl4

0.1 equiv.

40

N.R.

DMF

TMSOTf

0.1 equiv.

0 → r.t.

14

THF

pTsOH

0.1 equiv.

r.t.

11

MeCN

pTsOH

0.1 equiv.

r.t

12

DMF-Toluene (1:1)

pTsOH

Adjust pH ~3

50
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Mechanistically, the challenges associated with acetalization/ketalization of
glycals lies in the formation and stability of acetals, the stability of vinyl ethers and the
confirmation of the sugar ring. We attempted to address these issues by making a
variety of modifications. The formation of acetals and ketals under acidic condition is
reversible and is highly moisture sensitive. However, the conventional method of
benzylidenation is under acidic conditions. Therefore, the reversible reaction strongly
favors the starting material (Scheme 2.3.). Furthermore, vinyl ethers are also acid labile
and are susceptible to electrophilic additions and rearrangements. Electrophilic
additions of vinyl ethers are, unlike acetal formations, irreversible. Commonly available
nucleophiles for this side reaction are alcohols or water, which results in the formation of
an acetal or hemiacetal, respectively (Scheme 2.3.). Another type of side reaction that
occurs under these conditions is the Type II Ferrier rearrangement (Scheme 2.3.). While
the double bond is reduced in electrophilic addition, it migrates in a Type II Ferrier
rearrangement. Here, the group on C3 leaves following reaction with a Lewis acid, and
a nucleophile attacks at the anomeric carbon. This results in the formation of an acetal
or hemiacetal depending upon whether an alcohol or water acts as a nucleophile.
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Scheme 2.3. Acid Catalyzed Reactions Associated with Benzylidenation of Glycals.

Acetal Formation

Vinyl Ether Addition Reaction

Type II Ferrier Rearrangement

The above mentioned, three types of undesired reactions can be minimized or
eliminated altogether by removing the byproduct, such as methanol or water. Due to the
highly hygroscopic nature of unprotected glycals, they can hold some water and/or
methanol from the previous reaction. Therefore, reaction conditions need to be
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optimized to remove methanol/water before the acetal formation. Prior to the reaction,
the residual water and/or methanol was azeotropically removed in vacuo at a slightly
elevated temperature, 50 0C, for 1 0068our, from the solution of D-glucal 16 in DMFtoluene (1:1). Moreover, activated 4 Å molecular sieves were added along with
aldehyde or aldehyde dimethylacetal and pTsOH, in an effort to capture methanol as it
is produced. Thus, by optimizing the solution-based reaction conditions to remove
methanol, we have managed to improve the yields from low to moderate (Table 2.1.).
On the other hand, the removal of water still remains a problem and the yields of
benzylidenation with aldehydes is not satisfactory. The rationale is the difference in
boiling points. The boiling point of methanol is 64.7 0C, whereas that of water is 100.0
0C.

Likewise, the boiling point of methanol-toluene azeotrope is 63.8 0C, whereas that of

the water-toluene azeotrope is 84.1 0C. Glycals, like other monosaccharides, are
susceptible of thermal degradation at relatively lower temperature. Therefore, heating
up the reaction high enough to evaporate water is usually not an option. Thus, it is
obvious that removal of methanol from the sugar is feasible, but not removal of water.
Accordingly, under the assumption that D-glucal does not decompose below its melting
point of 58-62 0C, the benzylidenation reaction temperature was set to 50 0C.
The conformation of the sugar ring seems to be another factor in lowering the
yield of benzylidenation. Benzylidenation of pyranoses and pyranosides, that occupy
predominately a chair conformation, are reported at significantly higher yields79 than
glycals that exist in half-chairs, in the literature, as well as, in this work. As the resulting
acetal ring is fused to the sugar ring, fusing two chair conformation rings experiences
drastically less, if any, ring strain than fusing a chair with a half-chair. Furthermore, the
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ring strain present leads to distortion of the entire molecule which presumably results in
much more steric hindrance about the bulky aromatic ring. This ring conformation
cannot be altered but has to be addressed in order to explain the limitations of
improvement in yield.

Scheme 2.4. Attempts at Basic Benzylidenation.

Since the benzylidenation of glycals involves a reversible reaction, with the
equilibrium favoring the starting materials, benzylidenation under basic conditions was
attempted. It is known that gem-dihalo groups, with an exception of the difluoro group,
can react with diols to form acetals. A publication in 2000 by Kabalka, G. W. et al.80
reported a method to convert aldehydes to gem-dichloro methyl groups using boron
trichloride (BCl3). Thus, we attempted to utilize said method to synthesize pdichloromethylanisole 18. The treatment of p-anisaldehyde 17 with BCl3 refluxed in
hexanes presumably resulted in p-dichloromethylanisole 18. The structure of this
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intermediate was supported by 1H and 13C NMR: the dichloromethyl proton was
observed at 4.46 ppm and the carbon at 71.7 ppm. After purification by column
chromatography, the isolated yield of 18 was relatively low (51%) and the pure, clear
liquid compound turned to a dark color within 2 hours, indicating the compound 18 is not
stable at ambient environment for any length of time. In addition, Sawama et al.
reported that they were not able to isolate gem-dichloromethyl benzene with extraction
because of its instability.81
In the similar manner, we attempted gem-dibromination of toluene 19 with 6
equivalents of N-bromosuccinimide (NBS) and 5 mol% of zinc chloride (ZnCl2) (Scheme
2.4). Due to instability of gem-dihalomethyl benzenes and their derivative on silica gel
and a large excess of NBS, this method did not yield any reasonable amount of desired
gem-dibromo product. Although benzal chloride and benzal bromide are commercially
available, we still need a method to prepare substituted benzal chloride/bromide. Thus,
in situ generation of gem-dihalomethyl compound was considered. However, since the
acid has to be removed prior to benzylidenation under basic conditions but the products
are unstable upon most common purification means, the idea of in situ formation of
gem-dihalomethyl aromatic compounds remains challenging.
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Scheme 2.5. An alternative synthetic route of benzylidene glycal.

In another attempt to avoid acid for the benzylidenation, an alternative route was
planned out. The strategy was to cyclize the diol with a halide on the bridging carbon.
The chlorinated compound can be further utilized for a Suzuki cross coupling reaction
between a bora-substituted aromatic compound, catalyzed by palladium on carbon. To
install chlorine on the acetal carbon, we attempted to form the methylene acetal with
dichloromethane (DCM),82 chloroform was used to bridge the diol under basic condition
in N,N-dimethylformamide (DMF). The conditions used seemed to generate
dichlorocarbene and the desired reaction did not occur with our compound. The use of
bromoform, instead of chloroform, did not change the results. No further investigations
using this methodology were conducted.
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Scheme 2.6. A Novel Carbohydrate Template and Sites of Modifications.

1.
2.
3.
4.
5.
6.

Deoxy Pyranoses
Type I Ferrier Rearrangements
C-3 Derivatives
Epimers
Acetalization/Ketalization Derivatives
Ether Derivatives

With a moderate improvement in yield of synthesizing 12 (Table 2.1), we have
moved on to structural modifications of 12 that can not only improve the yield but also
could express better and/or different biological activities against CNS disorders. Using
the lead molecule 12 as a novel carbohydrate template, we have implemented six types
of modifications (Scheme 2.6.).
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Scheme 2.7. Deoxy Derivatives.

The first analogs we have prepared were deoxy compounds. As described
above, the vinyl ether is one of the major problems upon benzylidenation of glycals. To
address this problem, we have reduced the double bond between C1 and C2 to
eliminate the possibility of addition reactions and Ferrier rearrangements, and also to
change the ring conformation from a half-chair to a chair (Scheme 2.7.).
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The simple reduction was done on TAG 15, in ethyl acetate under hydrogen
atmosphere catalyzed by 5% palladium on carbon. The reaction progress was
monitored by hydrogen gas consumption as a function of change in pressure at room
temperature. Upon reaction completion, the solution was filtered through a Celite ® pad
and the filtrate was concentrated in vacuo. The crude product was purified by column
chromatography to yield a pale, yellow, liquid 21 in 93% yield. Treatment of 21 with
sodium methoxide in methanol followed by workup and purification yielded 1,2-dideoxyD-glucose 22 in 95% yield. Benzylidenation of the dideoxy sugar 22 afforded 83% of the
desired product 23 supporting the premise that the elimination of some side reactions
and a change in ring conformation can dramatically improve the yield of
benzylidenation.
Similarly, 2-deoxy-methylglucoside 26 was synthesized. This is especially an
interesting molecule to investigate the biological activity of, because the
monosaccharide is known to work as a glycolysis inhibitor.83 Triphenylphosphine
hydrogenbromide (TPHB) in methanol was used as the promoter to prepare 24. In this
reaction, methoxide from methanol act as a nucleophile for the addition at the anomeric
position. As the intermediate formed in the reaction is the anomeric bromide, its
departure leaves the ring oxygen as an oxonium ion, that gets attacked by methoxide.
An anomeric mixture of methyl glycosides is obtained. However, because of the
anomeric effect, the reaction was adequately stereoselective and α-β ratio of 13:1 was
obtained (77% yield). Pure α-anomer 24 was isolated (71% yield) via column
chromatography and was used for further reactions. Compound 24 was deacetylated in
the same manner using sodium methoxide in methanol to afford deprotected α-methyl-
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2-deoxy-glucopyranoside 25 (94% yield) which was benzylidenated to form 26, in high
yield (87%).

Scheme 2.8. Type II Ferrier Rearrangement Derivatives.
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The type I Ferrier rearrangement is another type of side reaction. By removal of
the byproduct, methanol or water, the formation of Ferrier product can be minimized.
However, in our structure-activity studies, Ferrier products are worth consideration.
Migration of the double bond consequently reduces its reactivity, and thus increases the
stability of the molecule while keeping the sugar ring shape relatively close to that of
glycals. For these reasons, we have prepared two Ferrier analogs 29 and 32 (Scheme
2.8.).
The first Ferrier analog is the methoxy adduct which is a byproduct from the
synthesis of the lead molecule 12. Following the procedure of Banaag et al.,84 Ferrier
rearrangement can be done on TAG 15 with methanol by treatment with boron
trifluoride diethyl etherate (BF3·Et2O) in dichloromethane (DCM) and acetonitrile
(MeCN) to afford 27 in 98% yield. The resulting compound 27 was deacetylated (99%
yield) followed by benzylidenation of the resulting diol (49% yield). Another approach to
synthesize the same molecule 29 is to treat D-glucal 16 with p-anisaldehyde
dimethylacetal and pTsOH under neat reaction conditions.85 In the preparation of 12,
the reaction is set at a higher temperature under reduced pressure to remove methanol,
in order to maximize the yield of 12 by minimizing the Ferrier product 29 formation.
However, by making the methanol available, we can achieve the Ferrier rearrangement
and benzylidenation in one step. The yield was slightly higher of product 29 (68%) using
this method indicating that the migration of the double bond away from the ring oxygen
makes the molecule relatively more stable.
To mimic the lead compound 12 better, 1-deoxy Ferrier analog 32 was prepared.
Following a procedure of Grugel et. al,86 triethylsilane was used as a hydride source and
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was added to C1 as a nucleophile. The reaction was carried out at 0 0C in DCM-MeCN
and was stirred at the same temperature for 90 min after the addition of BF3·Et2O. After
workup, 1H NMR confirmed the product was acceptably pure and the compound was
therefore used “as is”, without further purification. Deacetylation (in quantitative yield)
followed by benzylidenation afforded compound 32 (61% yield), again, supporting the
hypothesis of that migration of the double bond stabilizes the molecule.
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Scheme 2.9. Synthesis of C3 Derivatives – Hydrophobic Modifications.

Opium is a latex extracted from Papaver somniferum and comprises of over 20
alkaloids including the main component, morphine, and analogs thereof. 87 We were
inspired in our work by some of the analogs of opium and the structure activity changes
that occurred upon modification.
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Figure 2.4. Structures of Morphine and Derivatives Thereof.

Morphine

3,6-Diacetylmorphine

6-Monomethoxymorphine

3,6-Dideoxydihydromorphine

Acetylation has a significant affect in biological systems. There are numerous
enzymatic systems involving acetylation in our body and controlling molecular stability
and function. Moreover, acetylation is also very important in synthetic medicinal
chemistry including CNS drugs. For example, diacetylmorphine, also known as Heroin,
is a highly addictive controlled substance which was discovered in opium extracts and
that was intended for a pain treatment, but its potency was evaluated 2-3 times more
than that of morphine. Thus, although acetylation is a very simple and common
reaction, this small structural modification can alter the potency and molecular stability
to a great degree,88 and hence we were interested to see the effect of acetylation in our
molecule. Acetylation can be done on either D-glucal 16 or compound 12, but due to
selectivity issues and an expectation of low-moderate yields in benzylidenation, we
performed acetylation on compound 12. Treatment of 12 with acetic anhydride in

55

pyridine followed by workup and chromatographic purification yielded a pure white
powder of 33 (78% yield).
Similarly, methylation is a very commonly occurring biosynthetic reaction.
Codeine is another morphine analog in which the C3 hydroxyl group is methylated.
Codeine is used for pain, diarrhea, and in cough medications.89 In our body, CYP450
metabolizes codeine into morphine. Although codeine’s affinity to the μ-opiod receptor
is drastically reduced as compared to that of morphine, this negative result confirms the
importance of the phenolic hydroxyl group in morphine.90 In a like manner, we were
interested to see the importance of our C3 hydroxyl group. If the hydroxyl group is not
participating in receptor binding interactions, then increasing hydrophobicity will be
beneficial to improve bioavailability. Compound 12 was treated with sodium hydride
followed by methyl iodide to form a methoxyl group on C3. The reaction yielded 88% of
pure product 34.
Reden et al. synthesized various deoxy morphines and tested them for
antinociception (reduced sensitivity to pain) and opiate receptor binding.91 The SAR
results of 3,6-dideoxydihydromorphine 40 revealed that the phenolic OH was aiding the
receptor binding but not the main interaction to determine the binding affinity. The
authors believed that the binding interaction is depending on π-π interactions and
interestingly the C6 OH was interfering this binding activity. Therefore, along with
acetoxy and methoxy derivatives, we have synthesized the 3-deoxy derivative 35 to
evaluate the effect of C3 hydroxyl group on CNS activity. In addition, given the structural
similarity of 32 and 35, the comparison of the two compounds will elucidate the
importance of a vinyl ether double bond to receptor binding activity. The 3-deoxy analog
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35 was prepared via methylation of C3 OH followed by regioselective reductive
cleavage of an allyl ester using a one-pot radical reaction. The reaction afforded a white
solid, 72% over 2 steps, of product 35.
We have also attempted tosylation of the C3 hydroxyl group. The reaction went
smoothly and, per TLC, the reaction reached completion. Unfortunately, the tosylate 36
was very unstable and decomposed at ambient environment and was therefore not
suitable for any further application, including medicinal use. However, the tosylate can
be utilized for substitution reactions with various nucleophiles in future studies.
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Scheme 2.10. C3 Derivatives – Conjugated Ketone 46.

Oxidizer = MnO2, PDC, PCC or DMP reagent.

The conjugated ketone 46 is another intriguing analog. While hydroxyl groups
can be both hydrogen bond donors and acceptors, ketones can only be acceptors.
Moreover, the oxidation changes the hybridization at C3 from sp3 to sp2 which causes a
slight distortion of the shape of the sugar ring. Thus, the entire molecule will attain a
different shape and the relative locations of oxygens and the aromatic ring will be
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altered. In addition, although there are concerns regarding the molecular stability of 46
in the body because conjugated ketones are very reactive and susceptible to
nucleophilic conjugate addition or other micro addition reactions,92-94 ketones are useful
to develop other derivatives as described later.
There are a number of methods reported for the selective oxidation of C3
hydroxyl group on D-glucal.95-102 We have tried various oxidizers including: pyridinium
dichromate (PDC), pyridinium chlorochlomate (PCC), and manganese oxide (MnO 2).
Even though the selective oxidation of the allylic alcohol is feasible with those reagents,
after workup and multiple purification steps, the yield of 45 was lowered (12-67%). On
the other hand, the Dess-Martin Periodinate (DMP) reagent executed a cleaner
oxidation (58%), though the cost of the DMP reagent is high compared to other
oxidation methods, and also the DMP reagent is also shock sensitive.103, 104
Given the difficulty of separating the polar product 45 from the oxidizers used in
the reaction, a selective protection of the primary alcohol as a bulky trityl ether group
was attempted. The protection of 16 was achieved to form 41 in a moderate yield (70%)
and the subsequent allylic oxidation with PDC afforded a satisfactory yield of product 42
(95%). Though the ease of purification was greatly improved and higher yields were
accomplished at each step, the overall yield from D-glucal 16 to the conjugated ketone
45 was only 61% and the extra added steps did not justify their advantages. Ganguly et
al. reported a better approach to selective oxidation of glycal allylic alcohols using
barium permanganate (Ba(MnO4)2).105 The authors claimed Ba(MnO4)2 to be a better
oxidizer than MnO2. The procedure employed first required silylation of the primary
alcohol followed by the oxidation. The silylation yielded 6-O-TBDMS-D-glucal 43 in
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moderate yield but the oxidation in the second step occurred in low yield (22%), even
with an excess of oxidizer (12 equivalent). Since the oxidation itself was already a lower
yielding reaction than other methods, the overall yield would be significantly low in
compared to direct oxidation of D-glucal 16, we concluded that it was pointless to
proceed with the deprotection of the TBDMS group. As an alternative method, Tanaka
et al. reported selective allylic oxidation with a Pd/C catalyst, along with ethylene gas as
a hydrogen acceptor.106 Since ethylene gas was not readily available in our facility and
we prefer safer chemicals, we substituted ethylene gas with cyclohexene, also known to
act as a hydrogen acceptor. Unfortunately, this method did not give any significant
product.
Nevertheless, the oxidized D-glucal 16 was benzylidenated with a surprisingly
higher yield (68%). This is an indication of increased molecular stability due to the ring
shape change from hybridization changes at C3, as hypothesized above. Ultimately,
oxidation of the benzylidene compound 12 turned out to be the easiest method as well,
and was the highest yielding method among all the aforementioned methods. For this
oxidation procedure, PCC was found to be better than PDC because of its slight acidity.
PDC oxidation methods often involve the addition of acetic acid to aid the oxidation but
that can be risky with an acetal present. The acidity of PCC can also affect certain
acetals but most acetals are stable upon PCC treatment.107-109
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Scheme 2.11. C3 Derivatives – Imines, Oximes and Hydrazones.

As briefly mentioned above, reactions of nucleophiles with ketones vastly allows
the library of possible compounds to expand. Examples of reactions with ketones are
the stereoselective reduction to form a secondary alcohol,110, 111 the Wolff–Kishner
reduction112,113 to form a methylene group, reductive amination reactions to form
amines,114, 115 the Grignard reaction to form tertiary alcohols,116 as well as, the formation
of ketals,117 enamines,118 imines, oximes and hydrazones.119 In this project, we focused
on imines, oximes and hydrazones. The resulting compounds are conjugated and would
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not be in the most stable chemical state. However, introduction of nitrogen may make
the compounds more “drug-like”.120 The results of our syntheses are summarized in
Table 2.2. Further reduction of the C-N double bond will be carried out at some time in
the future.
Ketone derived imines, with the exception of the primary ketimine, are also called
Schiff bases. Schiff bases are common intermediates of biosynthesis and are formed by
the reaction of various enzymes with a primary amine source (such as lysine) in the
body. Our imines are conjugated Schiff bases. Conjugated Schiff bases are more
commonly used for utilities such as electrochromic devices121 and perovskite solar
cells122 rather than medicinal, utilizing their optoelectronic properties. However, because
of their biological relevance, it is interesting to explore the synthesis and evaluation of
some Schiff base derivatives. All the imine compounds were prepared following the
same method. Oximes were prepared likewise except for an additional step to
neutralize hydrochloric acid with sodium hydroxide prior to addition of sugar. All imines
and oximes were inseparable mixtures of E and Z isomers.
Hydrazone is also known as an intermediate of the Wolff–Kishner reduction112,113
in which a ketone is converted into a methylene group; an alternative method to make
the 3-deoxy analog 35. Hydrazone derivatives were synthesized in a similar manner to
the imines but THF was used as the solvent, instead of methanol. Considering the α
effect, the nucleophilicity of the terminal nitrogen of hydrazine is increased as compared
to that of amines.123 Accordingly, yields of 53 and 54 were higher than that of 47 and 48,
respectively. Like imines and oximes, both hydrazone analogs were isolated as a
mixture of E and Z isomers.
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Table 2.2. Results of Imine, Oxime and Hydrazone Derivatives.
NH2R

Product

Yield

Ammonia

47

33%

Aniline

48

39%

Ethylenediamine

49

68%

Propylamine

50

59%

Hydroxylamine

51

56%

Methoxylamine

52

63%

Hydrazine

53

48%

Phenylhydrazine

54

42%
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Scheme 2.12. C3 Derivatives – Attempted Fluorinations.

Similar to the 3-deoxy analog 35, we have attempted fluorinations at the C3
position to replace oxygen. Fluorine is widely used in the pharmaceutical field and about
20% of drugs contain fluorine124 because it is not only useful for visualization techniques
in metabolism studies, but also for its unique chemical properties that are suitable for
medicinal use. For example, Fluoxetine is a fluorinated antidepressant of the selective
serotonin reuptake inhibitor (SSRI) class and is one of the first very selective
antidepressants developed.125 Fluoxetine is also used for a treatment of OCD, bulimia
nervosa, and panic disorder. Unlike other halogens, fluorine forms a very strong bond
with carbon and, as a result, it increases hydrophobicity which is favorable in terms of
bioavailability.126 Thus, it is interesting to compare the biological activities of 35 and the
3-deoxy-fluoro analogs. In an attempt to mono-fluorinate, per Bandger et al., 6-O64

TBDMS-D-glucal 43 was subject to allylic fluorination with thionyl chloride and
benzotriazole in DCM followed by potassium fluoride (KF) in DMF.127 However, none of
the desired compound was formed under these conditions. We also attempted to
synthesize a difluorinated analog referencing a method published by Csuk et al.128 This
method, interestingly cleaved the benzylidene ring, but did not form gem-difluoro at C3
position as claimed.
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Scheme 2.13. C3 Derivatives – Attempted Synthesis of a Thioketone Derivative.

Lawesson’s reagent

Dihydropyranes

In addition, ketones can be converted into thioketones using Lawesson’s
reagent.129 Oxygen and sulfur both belong to group 16 and have some similarities in
their functions. Besides the size difference, the most noteworthy difference between
oxygen and sulfur is the ability to forming hydrogen bonds or the lack thereof. The
oxygen of the ketone is a hydrogen bond acceptor, but the sulfur of thioketone cannot
form a hydrogen bond, while C3 keeps the same hybridization and thus theoretically the
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same ring shape (e.g. distorted half-chair confirmation). The treatment of 46 with
Lawesson’s reagent in toluene seemingly afforded less polar product, according to the
TLC analysis. However, the product 55 was extremely unstable at ambient temperature
and on silica gel, and therefore, isolation of the pure product was not successful.
Obrecht et al. also synthesized dihydropyranothiones 57 and indicated the short shelf
life of the compounds due to their instability.130

Scheme 2.14. Attempted Formation of an Allal Derivative 58.
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Allal is a very rare C3 epimer of glucal and is not commercially available. Two
major routes to synthesize allal are: 1) elimination of D-allose, and 2) conversion of Dglucal to D-allal.131 However, both methods are multi-step reactions that lead to a
moderate to low overall yields of allal. Also, although carbohydrates in general are
relatively inexpensive, allose is an exception and is rather pricey, and therefore, we
needed to take another approach. Gaguly et al. and Garcia et al. have reported a
stereoselective reduction of C3 ketone132, 133 to produce an axial hydroxyl group on
glucopyanosides. In our attempts, both methods reported afforded regio- and
stereoselective reduction, but the stereoselectivity favored D-glucal, not D-allal. The
Luche reduction,134 employing cerium trichloride improved stereoselectivity but, for
particular purposes, the less stereoselective method, simple sodium borohydride
reduction, was better in terms of yielding more allal derivative 58. Conventional flash
column chromatography with silica gel afforded a mixture of products. Ion mobility LC
MS (provided by Waters Corporation, 34 Maple Street, Milford, MA 01757) were also
not successful in separating epimers for their mass analysis.
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Scheme 2.15. Syntheses of Galactal Derivatives.

63 % yield over 2 steps

Similar to D-allal, D-galactal is a C4 epimer of D-glucal. Unlike D-allal, D-galactal
is commercially available because D-galactose is naturally abundant and commercially
available. For example, D-galactose is one of the structural units of lactose, the “milk
sugar”. Since the benzylidene ring forms between C4 and C6, galactal analog 63
displays a great geometrical difference in comparison to 12: the distance between the
aromatic ring and the hydroxyl group as well as the orientation of the aromatic ring with
respect to the sugar ring differs. That is, despite the stereochemical change being
nominal, the galactal analog 63 is expected to exhibit totally different activity and affinity
to specific receptors.
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The galactal analog 63 was synthesized following the same procedure used for
12. The yields for this synthesis were slightly lower, due to the instability of a bulky
benzylidene group on an axial hydroxyl, though they were still satisfactory. However,
one noteworthy byproduct that was not observed in this reaction was the 2-deoxygalactopyranoside derivative 64. The formation of 2-deoxy-galactal analog 64 is timedependent and increases with the reaction time. We optimized the reaction time to be 2
hours, in order to obtain the highest yield for the galactal analog 63. Yet, 2-deoxygalactopyranoside 64 is a close analog of 26 and is also a very interesting candidate to
see the effect of axial group on C4. Luckily, 63 and 64 are easily separable with column
chromatography using silica gel, and therefore, both analogs were tested in vitro as
separate samples.
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Scheme 2.16. Syntheses of Acetalization/Ketalization Derivatives.

In order to investigate and optimize the best functional group(s), various
acetalization/ketalization analogs were prepared using aromatic aldehydes or dimethyl
acetals. To examine the effect of substituents on the aromatic ring, methoxy isomers
(ortho- 65 and meta- 66), methoxy mimics (p-N,N-dimethylamino 67 and p-methylthio
68) and other aromatics (phenyl 69 and p-trifluoromethyl 70) were also tested. In
addition, isopropylidene analog 71 was synthesized and tested as it resembles the
anticonvulsant, topiramate. Conventionally, acetalization with aldehydes are done neat
with freshly fused zinc chloride and we have followed this procedure for compound 66,
68, and 70. However, o-anisaldehyde and p-(N,N-dimethylamino)benzaldehyde are
solids at room temperature and thus are unable to dissolve D-glucal 16 for a neat
reaction. Furthermore, benzaldehyde is also available as benzaldehyde dimethylacetal.
Hence, compound 65, 67, and 69 were synthesized following the solution base method
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employed for all other benzylidenation reactions introduced above. Lastly, the
isopropylidene derivative 71 was prepared using 2,2-dimethoxypropane and D-glucal
16. The isopropylidene group is a ketone equivalent of aldehyde dimethylacetal.
Acetonitrile was used as the solvent to prepare this analog 71 and the reaction was
conducted at 0 0C. The results are summarized in the Table 2.3.
As discussed above, despite our attempts, we could not solve some of the
obstacles of glycal benzylidenation. Hence, the yields remained lower but we have
managed to synthesize enough for testing in cloned receptors. The solid aldehydes and
p-(trifluoromethyl) benzaldehyde gave particularly low yields in the benzylidenation
reactions. The solution method works better with aldehyde dimethylacetals, but not with
simple aldehydes. The p-(trifluoromethyl) benzaldehyde reaction was significantly low
yielding, despite the neat method used, because of the low solubility of D-glucal in said
aldehyde.
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Table 2.3. Results of Acetalization/Ketalization Derivatives.

Reactant

Solvent

Acid

DMFpTsOH
Toluene

Neat

ZnCl2

DMFpTsOH
Toluene
Neat

ZnCl2

DMFpTsOH
Toluene

Product

Temp.

Yield
(%)

50 0C

65

6

r.t.

66

28

50 0C

67

2

r.t.

68

15

50 0C

69

40

Neat

ZnCl2

r.t.

70

5

MeCN

pTsOH

0 0C

71

30
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Scheme 2.17. Syntheses of Ether Derivatives.

Yield 49%; mono- : di- : tri- = 1 : 1.3 : 1.8

PMB = p-methoxybenzyl

Throughout this section, it has been emphasized that benzylidene ring formation
is the biggest challenge in the chemistry for this project. Although we have designed our
syntheses to incorporate the benzylidene ring in our candidates, it is unclear if the cyclic
structure is an absolute necessity in order to obtain biological activity. Furthermore, we
also cannot deny the possibility of enzymatic or pH-driven acetal bond cleavage in the
body.135 Consequently, we believed it was worth testing the two possible ethers (72 and
73) and D-glucal itself 16 in the receptor assays. We started our ether synthesis with Dglucal, p-methoxybenzyl chloride and sodium hydride in DMF. After workup, column
chromatography purification yielded 3 products: per-substituted D-glucal, two
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disubstituted D-glucal and monosubstituted D-glucal 72. The disubstituted products
were an inseparable mixture of 3,6-di-O-(p-methoxy)benzyl D-glucal and 4,6-di-O-(pmethoxy)benzyl D-glucal. The monosubstituted product was the pure constitutional
isomer of 6-O-(p-methoxy)benzyl D-glucal 72. This method did not produce any 4-Omonosubstituted product 73. An alternative approach to synthesize ethers was the
regioselective cleavage of benzylidene ring. Treatment of 12 with lithium aluminum
hydride (LAH) and aluminum chloride (AlCl3) refluxing in DCM afforded 4-O-(pmethoxy)benzyl D-glucal 73.136 Likewise, a treatment of 12 with triethylsilane (TES) and
trifluoroacetic acid (TFA) in DCM at 0 0C yielded 6-O-(p-methoxy)benzyl D-glucal 72 in
72% yield.137

2.4.

Summary

We have elaborated a novel carbohydrate template based 12 and have
successfully synthesized a series of analogs for potential use as CNS disorder
treatments. The biggest challenge of our chemistry was the low yielding benzylidenation
reaction of glycals. We attempted an improvement of the synthesis of 12 using different
solvents, catalysts and stoichiometric amounts thereof, as well as, at various
temperatures. When we used a binary solvent system under reduced pressure with a
slightly elevated temperature (50 0C), we managed to remove the byproduct, methanol,
which led us to slightly higher yields than the conventional reported methods. Our
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attempts at basic benzylidenation and Suzuki reaction type approaches were not
accomplished. But, by means of modifications of D-glucal 16 (reduction/addition, Type II
Ferrier rearrangement and allylic alcohol oxidation), the yields of benzylidenation have
significantly improved. Most modifications made on the lead compound 12 afforded
moderate to high yields. Though stability concerns about analogs of oxidized 46 still
remain, a series of imine, oxime, hydrazone and thioketone were also prepared.
Depending on biological activity observed, compounds with sp2 hybridized C3 can be
optimized by better synthetic methods or reduced to corresponding compounds to
increase their chemical stability. Likewise, despite the low yields, various
acetalization/ketalization analogs were prepared and these can be optimized or the
syntheses modified further, if biological importance is proven. Lastly, two ether analogs
were synthesized in acceptable yields. The biological activities of ether analogs and Dglucal 16 will reveal the correlation between benzylidene ring and CNS-receptor binding
activities. Nonetheless, besides D-glucal 16 and the lead compound 12, 28 compounds
were synthesized and the total 30 compounds were tested in a series of CNS receptors.
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Chapter 3

Evaluation of A Novel Carbohydrate Template and Its Analogs for the
Treatment of Addiction, Epilepsy, Parkinson’s Disease and other CNS
Disorders

3.1.

Introduction

It is very important to understand neurotransmitter receptors as a means to
design medicinal compounds for treatment of CNS disorders. Neurotransmitter
receptors, also called neuroreceptors, are membrane proteins that, in response to
neurotransmitters, generate signal transductions. Despite the number of neuroreceptors
and varieties thereof, neuroreceptors are categorized mainly into two groups, G proteincoupled receptors (GPCRs) and ligand-gated ion channels (LGICs). Each group has
characteristic structural and functional similarities within the groups.138
The GPCRs are metabotropic receptors and are also known as seven
hydrophobic transmembrane (7TM) domain receptors. The GPCRs utilize second
messengers which are intracellular signaling molecules such as serotonin. The
examples139 of the GPCRs are the metabotropic glutamate receptors (mGluRs),
muscarinic acetylcholine receptors (M1-5), GABAB receptor, and dopamine receptors
(D1-5). The LGICs are ionotropic receptors and are transmembrane ion channel proteins.
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The IGICs, as they are named, are ligand-gated ion channels, and open the gate to
pass ions through in response to ligands’ binding. The ions include Na+, K+, Ca2+ and/or
Cl-. Unlike the GPCRs, the IGICs can be as simple as two domains which include the
extracellular domain with a ligand binding site and the pore. Examples of the LGICs are
GABAA receptors and the N-methyl-D-aspartate (NMDA) receptor.140
While there are dozens of CNS receptors, based on the pathologies of disorders
of our interest, details of receptors discussed in this section are focused on GABAA,
mGluR5, D2-like, norepinephrine transporter (NET), M2&4 receptors, 5-hydroxytryptamine
receptors (5-HTs) and Sigma 2 receptor. It has to be noted that many CNS receptor
proteins are difficult to isolate and the structure thereof is not fully understood. In
addition, due to their complexity, it is common that the pathology of diseases for which
they are effective and the mechanism of action of the treatments are not discovered in
their entirety.
As mentioned above, GABAA receptors are anion permeable LGICs, as well as
ionotropic receptors, and mediate inhibitory neurotransmission.141 GABAA receptors are
targeted for treatments of CNS disorders including epilepsy and anxiety disorders.
There are, so far, 19 receptor subunits identified, α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-3, and
functional receptors are composed of five of these protein subunits.142 The combination
of the five subunits assemble to form the pentameric structures, making GABA A
receptors complex and heterogeneous (Figure 3.1.). The pharmacological and
physiological profile of each receptor is highly dependent on the composition of this
assembly. Among the aforementioned 19 subunits, α1, β3, γ2 and δ are the subunits
known to be associated with epilepsy.143-146 The most commonly expressed GABAA
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receptors in the CNS are comprised of two subunits of α1, two subunits of β2 and one
subunit of γ2 (Figure 3.1). The chloride ion channel pore is located at the center of the
five-subunit-assembly, and ligand binding sites are located in between the subunits. The
major natural ligands of GABAA are γ-aminobutyric acid (GABA) 73 and benzodiazepine
(BDZ) 9. For the (α1) 2 (β2)2 γ2 pentamer, as depicted in Figure 3.1, the GABA active
binding sites are at the interface of the α1 and β2 subunits, and the BDZ allosteric
binding site is located at the interface of α1 and γ2 subunits.147 Medications such as
anticonvulsant drugs are designed to act as positive allosteric modulators at these sites.

Figure 3.1. Pentameric Structure of GABAA Receptor and Binding Sites.
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Figure 3.2. Examples of Ligands of GABAA Receptor.

Metabotropic glutamate receptor 5 (mGluR5) is a GPCR that is, along with
metabotropic glutamate receptor 1 (mGluR1), categorized in the Group I mGluRs.148 As
they are named, the natural ligand of the mGluRs is L-glutamate 74 (Figure 3.3.). Group
I mGluRs are known to activate phospholipase C, an enzyme that cleaves the
phosphate group from phospholipids. Activation of phospholipase C catalyzes the
release of phosphatidylinositol and phosphatidylcholine that can enter the
cyclooxygenase pathway and the lipoxygenase pathway to suppress inflammation. 149
Morphine 37 (Figure 3.3.) is an example of anti-inflammatory agent that agonizes
mGluR5. However, mGluR5 is also related to the rewarding properties of addiction, and
morphine itself is a highly addictive substance. There are mGluR5 antagonists, such as
fenobam 75 and 2-methyl-6-(phenylethynyl)pyridine (MPEP) 76 (Figure 3.3), that are
used to treat morphine addiction.150 Furthermore, mGluR5 is one of the CNS receptors
associated with cocaine addiction, and that modulates cocaine-induced plasticity.151
There are at least two distinctive allosteric binding sites on mGluR5 but the full structure
of mGluR5 is unknown.152
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Figure 3.3. Examples of Ligands of mGluR5.

Dopamine receptors are another class of GPCRs that regulate many important
functions including cognition, pleasure, memory and learning.153 There are at least five
subtypes of dopamine receptors, D1, D2, D3, D4, and D5. Some researches imply the
existence of D6 and D7 but any definitive confirmation has yet to be affirmed.154 The five
subtypes of dopamine receptors are classified into two families based on the G protein
coupling to: D1-like family to Gsα, and D2-like family to Giα. The D1-like family is
comprised of D1 and D5, and the D2-like family consists of of D2, D3 and D4. Coupling of
the D1-like family receptors to Gsα initiates activation of adenylyl cyclase, which
ultimately increases the intercellular concentration of the second messenger cyclic
adenosine monophosphate (cAMP). In contrast, coupling of the D2-like family receptors
to Giα inhibits adenylyl cyclase, which accordingly results in inhibition of the production
of cAMP.155 Dopamine receptors are associated with many disorders, including
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addiction,156, 157 Parkinson’s disease (PD)158 and ADHD.159 Specifically, D2 and D3 are
closely related to addiction, D2 is the primary dopamine receptor associated with PD and
D4 is relevant to ADHD. As they are named, the primary endogenous ligand of
dopamine receptors is dopamine 6. In the biosynthesis, dopamine 6 is a precursor of
norepinephrine 78, which is a precursor of epinephrine 79, and therefore there are
significant structural similarity among those three and thus they all can bind to
dopamine receptors. Likewise, L-DOPA 5 is a direct precursor of dopamine160 and, as
mentioned in Chapter 1, is a commonly used anti-PD drug. 46 Furthermore, highly
addictive substances such as cocaine 77, and methamphetamine 1 are ligands of
dopamine receptors. The structures of examples of ligands are shown in Figure 3.4.

Figure 3.4. Examples of Ligands of D2-like Dopamine Receptors and Norepinephrine
Transporter.
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Norepinephrine transporter (NET) is a monoamine transporter that is comprised
of 12 transmembrane domains.161 NET regulates the concentration of the extracellular
monoamine neurotransmitters, norepinephrine 78 and dopamine 6 (Figure 3.4.), and
because NET is a secondary active transporter, the reuptake of afore mentioned
neurotransmitters is sodium-chloride (Na+/Cl-)-dependent.162 Because NET regulates
the extracellular concentration of norepinephrine 78 and dopamine 6, like D2-like
receptors, NET is targeted for treatments PD,163 addiction164 and ADHD.165
Consequently, many compounds that have affinity to D2-like receptors also bind to NET
(Figure 3.4.).
Muscarinic acetylcholine receptors are GPCRs that interact with acetylcholine, a
transmitter in the CNS. There are five subtypes identified of the muscarinic
acetylcholine receptors (M1-5).166 M1, M3 and M5 are coupled with Gq proteins and
activation of these receptors ultimately activates protein kinase C and triggers release of
intracellular Ca2+. M2 and M4, on the other hand, are coupled with Gi/0 proteins and
activation of these receptors reduces the cAMP level and cAMP activation of protein
kinase A, by inhibiting adenylyl cyclase.167 M2 and M4 receptors are targeted for
Alzheimer’s disease treatments. Also, research has shown that M4 function is
associated with cocaine and heroin addiction,168 as well as Parkinson’s disease.169 The
natural ligands of the muscarinic acetylcholine receptors are muscarine 80 and
acetylcholine 81 (Figure 3.5.).
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Figure 3.5. Examples of Ligands of Muscarinic Acetylcholine Receptors.

5-Hydroxytryptamine receptors (5-HTs) are GPCRs that modulates the release of
various neurotransmitters and regulate the extracellular levels thereof. The endogenous
ligand of 5-HTs is 5-hydroxytryptamine, or more commonly known as serotonin 82. The
agonists of 5-HTs include lysergic acid diethylamide (LSD) 83 and 3,4-methylenedioxy
methamphetamine (MDMA) 84.170 5-HTs are targeted for the treatment of migraines,171
depression172, 173 and addiction.170

Figure 3.6. Examples of Ligands of 5-HTs.
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Sigma 2 receptor is an orphan receptor and details of which have not yet been
fully identified. Although the endogenous ligand is not known to date, 174 addictive drugs
such as methamphetamine (METH) 1,175 cocaine 77,176 and MDMA 84177 are known to
have high affinity to sigma 2 receptor (Figure 3.7.). Therefore, the sigma 2 receptor can
be a targeted for anti-addiction drugs.

Figure 3.7. Examples of Ligands of Sigma 2 Receptor.

3.2.

Background

The receptor binding profiles were provided by the National Institute of Mental
Health's Psychoactive Drug Screening Program. The protocols were conducted using
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procedures that are described in Chapter 4, and are available at
https://pdspdb.unc.edu/.
Our lead molecule 12, as mentioned in the preceding chapter, displayed binding
to GABAA and mGluR2 receptors. The Ki’s of 12 were 97.1 nM (average) for GABAA a1,
75.0 nM (average) for GABAA a2, and 81.0 nM (average) for GABAA a3. The primary
functional test at a constant concentration of 10 µM against mGluR2 showed 45%
antagonizing effect. Since not enough in vitro data is available, the mechanism is
unknown, but in vivo results have shown that 12 has seducing and weight gain effect for
epilepsy as well as anti-chronic and anti-inflammatory effects.
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3.3.

Results: Physicochemical Properties

The physicochemical properties were calculated with ChemDraw® professional,
as the details described in Chapter 4.

Table 3.1-1. Calculated Physicochemical Properties of the Series of Novel
Carbohydrate Benzylidene Derivatives.

Structure

ID

MW

Heavy
Atom
Counts

Rot.
Bonds

H-bond
Acceptors

H-bond
Donors

cLogP

TPSA
(Å2)

pKa

23

266.3

19

2

5

1

0.87

57.2

13.4

26

296.3

21

3

6

1

0.86

66.4

13.3

29

278.3

20

3

5

0

0.72

46.2

NA

32

248.3

18

2

4

0

0.95

36.9

NA

33

306.3

22

4

5

0

2.08

63.2

NA

34

278.3

20

3

5

0

1.87

46.2

NA

35

248.3

18

2

4

0

2.11

36.9

NA

46

262.3

19

2

5

0

1.3

54.0

NA

47

261.3

19

2

5

1

1.67

60.8

NA

48

337.4

25

3

5

0

2.9

49.3

NA

Calculated physicochemical properties of 23, 26, 29, 32, 33, 34, 35, 46, 47 and 48.
MW = molecular weight, cLogP = calculated partition coefficient, TPSA = total polar
surface area.
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Table 3.1-2. Calculated Physicochemical Properties of the Series of Novel
Carbohydrate Benzylidene Derivatives.

Structure

ID

MW

Heavy
Atom
Counts

Rot.
Bonds

H-bond
Acceptors

Hbond
Donors

cLogP

TPSA
(Å2)

pKa

49

304.4

24

4

6

1

0.77

75.3

9.8

50

303.4

22

4

5

0

2.29

49.3

NA

51

277.3

20

2

6

1

1.53

69.5

NA

52

291.3

21

3

6

0

2.12

58.5

NA

53

276.3

20

2

6

1

0.96

75.3

NA

54

352.4

28

4

6

1

3.9

61.3

NA

58

264.3

19

2

5

1

1.34

57.2

13.3

63

264.3

19

2

5

1

1.34

57.2

13.3

64

296.3

21

3

6

1

0.86

66.4

13.3

Calculated physicochemical properties of 49, 51, 52, 53, 54, 58, 63, and 64.
MW = molecular weight, cLogP = calculated partition coefficient, TPSA = total polar
surface area. The values in red are out of range of good predicted permeation/oral
bioavailability for CNS drugs, summarized by Pajpuhesh et al.67
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Table 3.1-3. Calculated Physicochemical Properties of the Series of Novel
Carbohydrate Benzylidene Derivatives.

Structure

ID

MW

Heavy
Atom
Counts

Rot.
Bonds

H-bond
Acceptors

Hbond
Donors

cLogP

TPSA
(Å2)

pKa

65

264.3

19

2

5

1

1.34

57.2

13.3

66

264.3

19

2

5

1

1.34

57.2

13.3

67

277.3

20

2

5

1

1.66

58.2

13.3

68

280.3

19

2

4

1

2.21

47.9

13.3

69

234.1

17

1

4

1

1.44

47.9

NA

70

302.3

21

2

7

1

2.36

47.9

13.3

71

186.2

13

0

4

1

0.51

47.9

NA

72

266.3

19

2

5

0

1.28

36.9

NA

73

266.3

19

2

5

0

1.28

36.9

NA

Calculated physicochemical properties of 65, 66, 67, 68, 69, 70, 71, 72, and 73.
MW = molecular weight, cLogP = calculated partition coefficient, TPSA = total polar
surface area. The values in red are out of range of good predicted permeation/oral
bioavailability for CNS drugs, summarized by Pajpuhesh et al.67

Based on our calculation, a good majority of our compounds fall into the range of
good predicted permeation/oral bioavailability for CNS drugs as described by Pajpuhesh
et al., and as discussed in Chapter 2. Compounds 49 and 53 have a calculated TPSA
that is out of range. TPSA is typically used as one of the parameters to evaluate the
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permeability of drug candidate through membranes including the BBB. That is, the less
the TPSA, the greater the likelihood of a compound passing through lipophilic
membranes. However, our compounds are carbohydrates and, therefore, they are likely
to be able to utilize glucose transporters (GLUTS) to enter the brain, instead of taking
transcellular lipophilic pathways. Hence, we consider that the relatively higher TPSA of
49 and 53 would not be an issue. Likewise, the number of hydrogen bond acceptors for
compound 70 is outside of the acceptable range for CNS drugs, due to the three
fluorine atoms of the trifluoromethyl group being hydrogen bond acceptors. Although it
is true that fluorine accepts hydrogen bonds, the bond strength of F---H is between 2 to
3.2 kcal/mol whereas that of O---H is between 5 to 10 kcal/mol.178 The weaker hydrogen
bond between fluorine and hydrogen is on account of the weaker electrostatic influence
of fluorine. The number of hydrogen bond acceptors typically affects the polarity of the
molecule and thus the permeability thereof. Thus, the poorer electrostatic influence of
fluorine affects the polarity and permeability to a lesser extent. Furthermore, because 70
is a carbohydrate, it would likely go through membranes via GLUTS rather than by
passive permeation.
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3.4.

Results: Biological Activity and SAR Analysis

Table 3.2-1. Primary Binding Assay Results.
ID

5-HT1A

5-HT1B

5-HT1D

5-HT1E

5-HT2A

5-HT2B

5-HT2C

5-HT3

23
26
29
32
33
34
35
46
47
48
49
50
51
52
53
54
63
64
65
66
67
69
70
71
72
73

0.7
-4
3.3
-2.9
15.4
5.1
14.5
43.4
0.8
5.8
13.1
19.6
-0.8
-1.7
7.1
2
0
2.7
1.7
5.2
2.4
0.6
15
9.4
-0.7
0.6

10.4
1.6
-5.2
-0.6
-5.7
-2.1
10.2
4.1
11.7
19
21.6
35.9
-15.9
-4.3
1.6
4
-4.2
-11.7
2.5
-8.2
-6.1
-15.4
4.9
-15.8
-10.5
-2.4

48
-6.6
0.1
-8.3
-1.4
-1.1
-10.3
-5.5
-1
2.1
4.5
8.4
-16.1
-14
-2.5
1.6
6.9
-5.2
-7.1
-16.1
0.5
-12.8
-4.4
-13.4
-14.3
-14.1

11.6
-5.6
-5.1
-6.1
-11.9
-6.9
6.4
-9.3
11
6.3
28.9
5.9
-6.1
-2.5
4
11.6
-6.2
-1.3
1.5
16.6
-1.4
-1.8
15.7
3
2.7
0.8

33.8
-12.4
-10.2
-12.3
-0.2
-1.5
0.9
8.4
-24.2
-5.6
-6.9
-6.6
2.7
0
-11.5
-5.6
-9.8
-7.9
-5.6
-1
-9.2
0.5
0.5
-1.9
1.5
-5

17
19
12.6
11.6
12.3
33.1
16.7
39.1
15.5
65.2
23.7
25.3
27.5
-6.8
10.5
45.3
11.1
22.7
10.3
21.2
10.9
-13.1
26.8
-0.4
2.4
0.5

2.1
5.1
1.9
-6.4
5.6
-5.8
42.9
6.8
3.2
21.9
45.4
-12.4
-16.3
-5.6
17.8
34.9
2.5
1.3
-14.7
4
-3.1
-15.2
26.1
16.6
-7.6
0.3

-4
-12.8
-17.5
-18.8
15
3.3
-3.9
-17.2
-14.2
-1.4
13.3
-10.9
-14.5
-18.1
-6.7
-11.4
-5.7
-11.8
-15
2.1
-19.8
-19.8
11.6
-18.1
-12.7
-17.1

Primary receptor binding results for 5-hydroxytryptamine receptors (5-HT1-3). Value(s)
highlighted with yellow indicate >50% inhibition.
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Table 3.2-2. Primary Binding Assay Results.
ID

5-HT5A

5-HT6

5-HT7

Alpha1A

Alpha1B

Alpha1D

Alpha2A

Alpha2B

Alpha2C

23
26
29
32
33
34
35
46
47
48
49
50
51
52
53
54
63
64
65
66
67
69
70
71
72
73

15.9
-0.6
2.8
-7.1

0.6
4.7
11.5
11.9
-32.8
-34.3
-32.9
20.1
-46.8
-33.7
-32.7
-34.1
-46.7
-19.4
1.6
-26.5
22.9
13.8
-43.2
-32
-11
-24.6
-14.7
-13.7
-64.1
-36.5

21.9
-17.4
-3.7
6.8

8
-5.5
3.1
3.8

2.7
-3.5
-2.6
-8.4

3.0(AVE)
22.5
-7.7

6.7
7.8
25.9
0

-19.7
-7.4
7.7
86.6

0.7

17.5
-17.8
-10
-18.4
-16.1

-8.2
-5.7
-6.8
-16.8
-17.7
-18.3
-11.4
-1
8.8
-0.9
-5.1

-17.4
-6.1
-14.4
2.9
-13.3
-12
-2.6
-0.6
-14
-13.3
-4.1
-15.7
-12.3
-0.3
-8.3
6
-0.4
-3
25.4
10
-0.8
-14.1
5.4
1.5
23.6
35.6

-14.3
-7.2
19.8
-13.1
18

3.7
0.1
0.4
18.1
11.6

91.6

1.1
5.6
1.1

7.6
-19.9
35.4
40.7

4.5
41.7
15.2
-2

1.7

46.1

-1.3

48.6

42.8

6.6

-17.1

-4.3
8.7

-0.1

2.8

-11.7
-14.8

-6.3

-15.1
-12.6
4.2
-2

4.2

16
-17.5

-5.2

-11.7

Primary receptor binding results for 5-hydroxytryptamine receptors (5-HT5-7) and
adrenergic receptors (α1-2). Value(s) highlighted with yellow indicate >50% inhibition.
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Table 3.2-3. Primary Binding Assay Results.
ID

Beta1

Beta2

Beta3

BZP Rat
Brain Site

D1

D2

D3

D4

D5

23
26
29
32
33
34
35
46
47
48
49
50
51
52
53
54
63
64
65
66
67
69
70
71
72
73

-11.8
13.1
-15
-2.6
-13.2
-14.3
-16.9
0.3
36.1
19.8
14.7
6.1
13.6
30.5
18.6
14.7
-10.3
24.1
13.9
37.8
4.1
38.9
-16.3
-3.5
3.1
11.9

-7.6
-9.9
6
-8.8

-17.2
-8.3
7.9
11.1
1.5
14.9
0.7
-2.5
-1.7
-4.1
3.8
-0.5
1.9
5.2
-4.2
4.4
13.9
3.2
-1.8
8.9
12.9
-7.5
24.3
10.8
-7.2
-6.8

-4.9
-15.6
6.9
9.1
35
-3.9
20.6
37.7
23.9
29.3
50
50
-5.8
-2.1
27.2
50
-2.9
4.2
18.5
21.1
-4.3
1
18.6
-5.6
8.3
16.1

-16.6
-3.2
-1.5
-2.7
-6.1
3.3
-12.1
11.7
19.2
18.9
-19.5
-9.7
-16.9
-5.6
32.7
44
-10
-4.4
-18.5
-0.2
4.7
-5.4
-2.6
7.7
-6.1
-15.9

25.2
-11.9
-17.3
-9.5
-8.3
-9.6
-2.1
59.9
-0.2
-3.9
-2.5
10
-17.7
-4.2
0.4
-13.4
11.1
-10.9
-13.6
-8.3
-15.9
14
-12.9
-10.2
25.1
-11.1

16
-13.6
-14.9
-4

-4.1
0
8.9
1.5

8.1
17.7
30.8
13

70.4

75.9

6.9

-14
-12.9

4.4
28.9

36
15

-16.5

8.8

-1

-12

13.6

2.4

-0.7

-7.7
2.5

-7.9

-4.4

Primary receptor binding results for adrenergic receptors (β1-3), benzylpiperazine (BZP)
rat brain site and dopamine receptors (D1-5). Value(s) highlighted with yellow indicate
>50% inhibition.
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Table 3.2-4. Primary Binding Assay Results.
ID

16
23
26
29
32
33
34
35
46
47
48
49
50
51
52
53
54
63
64
65
66
67
68
69
70
71
72
73

DAT

DOR

GABA a1

GABAA

GABAa a5

34.3
7.4
12.8
-13.7
-9.5

-2.9

2.3
-0.8

-10.3

-10.3
24.7
-13.1
-7.6
9.8
17.5
4.8
2.9
53.8
30.8
33.4
36.3
31.4
44.2
23.7
41.5
-11.1
-13.5
0.2
15.7
-4.9

-19.2

H2

H3

H4

-7.1
-6.9
0.4
-8.5
-12.7
-9.7
5.4
4.1
25.2
30
14.9
9
26.7
24.2
-8.1
7.9
8.1
-3.7
-6.2
-5.1
-8.9

1.4
-10.9
-7.6
20.3
19.1
4
5.7
-7
7.5
5.6
7
12.3
6.8
5.4
-0.2
-4.2
-18.4
-3.5
1.3
16.2
1.3
-14.8

-6.2
-2.4
0.5
-3.1
3.5
-4
7.7
-3
-15.4
-5.7
5
5.7
-3.8
-6.2
-12.5
-17.6
-1.9
-2.9
-5.2
-18.3
0.6

-2
7.1
-3.8
-18.6
-18.6
-12.8
-6.4
-17.4
-14.4
1
-8.3
6.1
-19.7
-7.4
-6.1
5.3
4.9
-13.2
-19.2
0.8

-14.3
-6.4
-4.7
-10.3
-15.5

-0.1
-10.9
-1.5
15.1
-0.7

-15.4
31.6
3
-4.8
0.8
-6.7
-22
-30.1
-5.1
17.3
30.4
5.7
5.2
-4.7
4.6
25.2
37
-0.3
-8.1
-41.7
-44.6
-5.5

41.3
43.7
16.1
-2
0.8
16.1

H1

-13.2
20.1
25.4
-10.2
36.4
-4.8

21.2
-10.6
34.8
30.3
-0.9

-1.3
5.7
-10.5
5.6

Primary receptor binding results for dopamine transporter (DAT), δ-opioid receptor
(DOR), γ-aminobutyric acid A (GABAA) receptors, and histamine receptors (H1-4).
Value(s) highlighted with yellow indicate >50% inhibition.
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Table 3.2-5. Primary Binding Assay Results.
ID

16
23
26
29
32
33
34
35
46
47
48
49
50
51
52
53
54
63
64
65
66
67
68
69
70
71
72
73

KOR

M1

M2

M3

M4

M5

mGlur5

mGluR5_RatBrain

90.3
2.9
-9.9
-3.9
-1.1

-10.6
-10.9
3.7
-9
-5
5.7
17.5
46.5
-0.2
14.5

3.6

8.5
-16.2
9.3
-0.1
-15.9
-10.1
-15.5
-1.8
-17.5
-7.4
-16
-13.5
-9.7
-15.5
-4.7
-16.9
-6.1
-14.8
-14.8
-19
-5

6.6
20
18.4
-7.8
-10.6
-13.7
-12.9
1.7
-0.2
-5.1
8.7
2.1
5.8
11.3
-3.8
16.7
-7.2
-15.5
-12.4
-5.7
-12.8

-1.3
-6.2
-7.7
-9.3
-0.4
-0.7
4.3
-3.2
-11.9
-9.6
-5.6
-12.7
-14.5
-9.5
8.3
5.1
-10.5
7.4
3.1
-9.8
-1.7

2.5
-0.6
6.4
-24.7
-6.6
4.4
-2.6
-20.7
-12.7
-11.2
-8.4
-6
-9.5
-11.6
8.3
-4.4
-6.1
-15.5
-8.6
8.8
-15.3

-4.2
18.5
-2.5
10.4
-1.1
5.9
12.2
-3.3
-5.7
-2.4
-6
-4.3
-11.4
-8.9
-5.9
1.1
-14.8
-3.4
-7.3
4.9

3.2
-0.6
50

45.9

12.3
-9.8

13.5
26.8

1

-7.9
-18.2
-6.9
-4.4
1.9

9.9
-11.3
-25.9
15.1
17.9

-10.5
-3.9
3.8
-14.1
-4.1

0.8
-7.1
-18.4
-1.8
3.4

5.1
-6
1.8
-7.2
-5.1

27.3

Primary receptor binding results for κ-opioid receptor (KOR), muscarinic acetylcholine
receptors (M1-5), and metabotropic glutamate receptors (mGluR5). Value(s) highlighted
with yellow indicate >50% inhibition.
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Table 3.2-6. Primary Binding Assay Results.
ID

16
23
26
29
32
33
34
35
46
47
48
49
50
51
52
53
54
63
64
65
66
67
68
69
70
71
72
73

MOR

NET

NMDA

PBR

SERT

Sigma 1

Sigma 2

-6.2
-15.9
9.5
13.7
-5.2
-3.7
-0.7
7.8
9.6
-33.2
15.7
8.1
7.8
16.7
-0.2
40.2
0.2
-9.5
4.6
16.7
6.9

-5.9
91
-10.9
75.5

-12.9
4.3
-1.9
-8.6
-0.1
7
4
39.1
0.3
-14.4
-4.8
27.1
10.9
11.4
-4
10.5
4.8
3.8
-5.3
0.9
-1

-7.6(AVE)
-25.1
-3.4
-18.3
2.3
1
-10
-19.1
-27.2
-8.2
-30.3
-26.9
-5.9
-7.7
-9.1
-0.8
-17.2
-19.1
35
28.3
-16.3

6.7
-15.2
-0.9
4.5
4.5

-29.4
20.9
-15.8
27.1
37

-3.3
27
15.2
-17.4
7
29.7
40.7
48.7
8.4
22
18.6
32.3
27.3
19.9
31.8
31.9
-12
-0.8
-13.6
40.8
34.7
-4.3

-11.8
-7.9
-8.2
40.3

52.5

-6.8
-12.8

2

86.5

-4.8
-11.4

0.4

-4.5
28.4
44.7
-2.7
40.2
48.2

6.1

15.3
25.3
-7.7
9.2
7

9.5

Primary receptor binding results for μ-opioid receptor (MOR), norepinephrine transporter
(NET), N-methyl-D-aspartate receptor (NMDA), peripheral benzodiazepine receptor
(PBR), serotonin transporter (SERT), Sigma receptors 1 and 2. Value(s) highlighted
with yellow indicate >50% inhibition.
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First and foremost, no compound in our test set showed the same activity as our
lead compound 12. Unfortunately, deoxy pyranose analog 23 did not show any binding
activity. Although another deoxy pyranose analog 26 showed selective binding affinity to
SERT, the secondary binding result revealed the Ki was over 10,000 nM (not shown),
and thus, the receptor affinity is quite weak. Taking these two results into consideration,
it is very likely that the existence of a double bond in the pyranose ring is necessary, for
the confirmation to fit into the binding pocket and/or participating in the binding
interaction.
One of the Type I Ferrier rearrangement analogs 29 did not have any specific
binding activity. On the other hand, the other Type I Ferrier rearrangement analog 32
bound to mGluR5 and SERT but the secondary binding result of SERT determined the
Ki to be over 10,000 nM (not shown), indicating that the binding affinity of 32 to SERT is
negligible. Considering 26 did not bind to any receptors adequately either, the methoxy
group at the anomeric position may be interfering the molecule binding to receptors. In
future experiments, it will be interesting to see if the β-analogs of 26 or 29 will show any
binding activity.
C3 derivatives with no altered hybridization, 33, 34 and 35, were also tested but
did not show any binding. This suggests that the OH group of 12 is actually participating
in the binding interaction. More specifically, it is likely that the hydrogen atom of the C3OH is acting as a hydrogen bonding donor increasing affinity for GABAA receptor.
Moreover, the comparison between compounds 32 and 35 implies that the double bond
in 32 is not only dictating the ring shape to fit in the binding pockets of receptors but
also somehow participates in the binding interaction.
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Introducing sp2 hybridization at C3 revealed some interesting results. 46 bound
to α2C, D2-like dopamine receptors (D2, D3 and D4), NET, and SERT. As mentioned
above, D2-like receptors and NET share the same ligands. Hence, it is understandable
that 46 possesses significant affinity to all D2-like dopamine receptors as well as NET.
The secondary binding results of 46 determined the Ki to α2C and SERT to be over
10,000 nM (not shown), again, indicating the binding is non-specific. Compound 47
bound to the DOR receptor selectively. Compounds 46 and 47 are structurally very
similar but they have binding affinities to significantly different receptors. Likewise,
although 48 bound to 5-HT2B selectively, 54 showed inhibition against benzylpiperazine
(BZP) receptor. Similarly, 49 and 50 showed some affinity to BZP receptor.
Unfortunately, oximes (51 and 52) did not bind to any receptors. Therefore, the space
around C3 is critical for the molecule to fit into a binding pocket. In addition, neither one
of the hydrazone analogs (53 and 54) showed notable binding results, supporting the
hypothesis regarding the space required around C3. Furthermore, the double
hyperconjugation of hydrazone derivatives could have been interfering with the binding
activity as well. However, for compounds 47 to 54, testing separate E and Z isomers is
required, in order to make any definitive conclusions about binding as these samples
are mixtures.
We have attempted to prepare two epimers of 12. Since 58 was a minor
component of an inseparable mixture with 12, 58 was not tested for receptor binding
activities. However, the galactal analog of 12 (63) and the C4 epimer of 26 (64) did not
show any significant activity on CNS receptors. The biggest differences that C4 epimers
exhibit are the overall shape of the molecules and the geometrical location of the
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aromatic ring. Since both 63 and 64 are inactive, their molecular shapes seem
unsuitable for receptor binding. The results also imply that the binding interactions are
not localized solely on the D-glucal motif, which will be further investigated.
The acetalization/ketalization derivatives (65-71) all lacked activity on CNS
receptors, supporting the hypothesis that an aromatic ring participates in binding
activities. Compounds 65 and 66 have methoxy group at ortho- and meta- positions,
respectively, of the aromatic moiety, and did not show significant binding affinity to any
receptors. This could be due to steric hindrance which occurs when the methoxy group
is located at a certain position. Compounds 67 and 68 are nitrogen and sulfur analogs,
respectively, of the p-methoxy phenyl group. This, again, could be a steric issue
because nitrogen has an extra methyl group on it and sulfur is bigger than oxygen.
However, the result of 69 was also negative, suggesting that the issue with 65-68 was
not a steric hindrance but, instead, the methoxy group is a necessary component and
also it has to be located at para-position. The result of 70, as well, proved that it has to
be p-methoxy group. However, despite the negative primary binding results, additional
tests were done for 65, 66 and 68, and the results were reported and discussed later in
this Chapter.
Lastly, ether derivatives (72 and 73) and D-glucal (16) were tested and their
results compared to see the necessity of acetal motif for CNS receptor binding. Based
on the primary binding results, D-glucal 16 showed selective inhibition of mGluR5 but
did not show the same activity as 12. The negative results of 72 and 73 also support
that the cyclic acetal is a necessary factor. The cyclic acetal motif caps the polar
hydroxyl group, making it more hydrophobic. In addition, because it is a cyclic form, the
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acetal ring locks the geometrical position of the aromatic ring and the sugar ring for the
best fit to the binding pockets. Combined with the fact that the activities of 12 have been
proven in vivo, we can assume that at least the majority of 12 survives from enzymatic
cleavage throughout the metabolic pathways, and the activities shown are of 12 instead
of metabolites thereof. Furthermore, topiramate has two 5-membered isopropylidine
rings fused with the sugar ring but the clinical data showed that at least 55-66% of orally
administered topiramate is secreted unchanged in urine.179 Thus, despite the acid
instability, the acetal ring is likely to survive metabolism and also it is a critical
component for the activity.
Compounds with significant primary binding results (>50% inhibition) or those of
particular interest were tested for secondary binding to determine the binding affinity
(Ki). Some compounds were further tested for their function to determine whether the
binding is agonizing or antagonizing the receptor activity, as well as to determine the
half maximal inhibitory concentration (IC50) when the function is significant at
reasonable concentration. The secondary binding results with K i < 10,000 nM and
functional test results are shown hereafter.
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Figure 3.8. Secondary Binding Results – mGluR5.

Compound: 16 (14684)
Receptor: mGluR5_RatBrain
Hot Ligand: MPEP
Species: Rat
Source: Brain
Ki : 3,483 nM

Compound: 32 (40432)
Receptor: mGlur5
Hot Ligand: [3H]MPEP
Species: Human
Source: Cloned
Ki: 2.4 nM
MTEP = 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine, MPEP = 2-Methyl-6(phenylethynyl)pyridine
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Table 3.3. Primary Functional Results – mGluRs.
ID

12
AGO

16
ANT

AGO

68
ANT

AGO

ANT

mGluR1a
-1
-16
-4
90
9
88
mGluR2
-4
45
16
95
14
103
mGluR4
-3
-1
-7
97
21
109
mGluR5
-5
3
-12
94
18
55
mGluR6
-5
3
-12
94
18
109
mGluR8
-4
1
23
87
4
97
AGO = agonist, % activation, ANT = antagonist, % inhibition. Value(s) highlighted with
yellow indicate >50% activation/inhibition.

Based on the primary binding results, we have tested 16 and 32 for mGluR5
secondary binding activities were followed by functional tests for 32. The Ki of 16 for
mGluR5 was 3,483 nM, which is significantly higher than 23 nM, the Ki of a known
mGluR5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP) 85. The
primary functional tests on various mGluR’s were done for 12, 16 and 68. Both 16 and
68 showed better results than 12. However, although the primary functional test showed
that 16 has significant antagonizing effect on multiple mGluR’s, the concentration of 16
tested was 10 µM, higher than its Ki. Similarly, 68 was tested for the primary functional
tests and showed antagonizing effects. Additional testing is required to elucidate the
detailed potential of 68 as mGluR’s antagonists. Nonetheless, since the Ki of D-glucal
16 was significantly lower than the reference, the data at least justifies the idea that the
modifications on D-glucal 16 improve its functions and make it more suitable for
medicinal use, rather than D-glucal 16 itself is working as a drug.
On the other hand, the Ki of 32 was 2.4 nM, which is comparable to the reference
value, 2.3 nM, of Fenobam 75 (Figure 3.8.). Fenobam 75 is a potent and selective
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negative allosteric modulator of mGluR5 and the anxiolytic efficacy is comparable to
that of benzodiazepines.180-183 Hence, a secondary functional test for compound 32 was
conducted (Figure 3.9.).
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Figure 3.9. Secondary Functional Results – mGluR5.

Compound: 32 (40432)
MTEP = 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine, L-Glu = L-glutamate, RFU =
relative fluorescence unit, RLU = relative luminescence unit

104

The secondary functional test of 32 on mGluR5 was done in the presence of 80%
effective concentration (EC80) of L-glutamate (L-Glu), a natural ligand of mGluR5, and
the result obtained was compared to L-Glu alone as well as MTEP 85 (Figure 3.9.). As
expected, unlike L-Glu, our compound 32 and MTEP 85 did not show any agonizing
activity. However, while MTEP 85 clearly showed antagonizing activity, our compound
32 did not display any significant antagonizing activity. This indicates that the compound
32 is likely to bind to the same binding site as L-Glu and does not initiate dissociation of
L-Glu.

Figure 3.10. Structures of Compounds Used for mGluR5 Tests.
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Figure 3.11-1. Secondary Binding Results – D2-like Dopamine Receptors.

Compound: 46 (40433)
Receptor: D2
Hot Ligand: [3H]N-Methylspiperone
Species: Human
Source: Cloned
Ki: 855.0 nM (average)

Compound: 46 (40433)
Receptor: D3
Hot Ligand: [3H]N-Methylspiperone
Species: Human
Source: Cloned
Ki: 1018.0 nM (average)
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Figure 3.11-2. Secondary Binding Results – D2-like Dopamine Receptors

Compound: 46 (40433)
Receptor: D4
Hot Ligand: [3H]N-Methylspiperone
Species: Human
Source: Cloned
Ki: 1260.5 nM (average)

As shown in Figure 3.11. Compound 46 was further examined for binding activity
to D2-like dopamine receptors (i.e. D2, D3, and D4). The Ki of 46 to D2 was 855.0 nM in
average, whereas the reference Ki of haloperidol 87 was 2.5 nM. Likewise, the Ki of 46
to D3 was 1018.0 nM in average, which was higher than the reference value of 2.2 nM,
the Ki of chlorpromazine 88. The Ki of 46 to D4 was 1260.5 nM in average, higher than
the reference value of 9.7 nM, the Ki of chlorpromazine 88. Haloperidol 87 is an inverse
agonist of D2-like receptors and chlorpromazine 88 is also a very effective antagonist of
D2-like dopamine receptors.
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Figure 3.12. Secondary Functional Results – D3.

D3 Antagonist assay
25000

40433+EC80 Quinpirole
Haloperidol+EC80 Quinpirole

EC80: 0.1M Quinpirole
20000

RLU

15000

Quinpirole

10000
5000
0
-12
-5000
LogIC50

Compound: 46 (40433)

LogIC50
IC50

-11

-10

-9
-8
log[Drug], M

-7

-6

-5

-4

40433+EC80 Quinpirole Haloperidol+EC80 Quinpirole
-5.862
-7.100

40433 +
EC80 Quinpirole
-5.862
1.37 μM

Haloperidol +
EC80 Quinpirole
-7.100
0.08 μM
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Compound 46 was also tested for its function against the D3 receptor (Figure
3.10.). Quinpirole 89 was employed as a reference agonist, as well as the competitive
substrate with a concentration of the EC50 for the antagonizing test. Haloperidol 87 was
employed as a reference antagonist. As expected, our compound 46 did not show any
agonizing effect with D3 receptor. On the other hand, 46 showed considerable
antagonizing effect with an IC50 of 1.37 µM. Haloperidol 87 is used for a wide variety of
symptoms including alcohol addiction and schizophrenia.183 Haloperidol 87 is an inverse
agonist of D2-like receptors but also affects other receptors such as the D1-like
dopamine receptors, 5-hydroxytryptamine (5-HT) receptors, sigma1&2 (σ1&2) receptors,
histamine1 (H1) receptors and muscarinic acetylcholine1 (M1) receptors.184-189 Thus,
haloperidol is not the most selective agonist of D3. In addition, haloperidol is well known
for its adverse side effects such as Parkinsonism, hypotension, and prolonged QT.190
Hence, although our compound 46 has a higher IC50 than that of haloperidol, 46 is more
selective and may have fewer side effects. This will be further elucidated with additional
toxicology tests.
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Figure 3.13. Secondary Functional Results – D4.

D4 Antagonist assay
15000
EC80: 0.03M Lisuride

40433+EC80 Lisuride
Nemonapride+EC80 Lisuride
Lisuride

RLU

10000

5000

0
-12

-11

-10

-9

-8
-7
log[Drug], M

-6

-5

-4

Compound: 46 (40433)

D4 functional assays were conducted with lisuride 90 as a reference agonist and
nemonapride 91 as a reference antagonist (Figure 3.13.). The agonist assay showed
that 46 has no agonizing effect on D4. In the agonist assay, with an EC80 level for
Lisuride, 46 did not display any significant antagonizing effect, implying that 46 does not
have the desired affinity in a competitive binding environment. On the other hand, this
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result makes 46 very selective to the D3 receptor and thus 46 may have less of a
chance of having adverse side effects.

Figure 3.14. Structures of Compounds Used for D2-like Receptors Test.
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Figure 3.15. Secondary Binding Result – NET.

Compound: 46 (40433)
Receptor: NET
Hot Ligand: [3H]Nisoxetine
Species: Human
Source: Cloned
Ki: 7945 nM

Compound 46 was also tested for secondary binding to NET. The result was
compared to a NET inhibitor, desipramine, as a reference. The Ki of 46 was 7945 nM,
whereas that of desipramine was 2.5 nM. That is, 46 does not bind to NET in any
significant degree and, therefore, 46 is still very selective to the D3 receptor.
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Figure 3.16. Structures of Compounds Used for NET Test.

Figure 3.17. Secondary Binding Result – M2.

Compound: 71 (40439)
Receptor: M2
Hot Ligand: [3H]QNB
Species: Human
Source: Cloned
Ki: 6772 nM
QNB = 3-quinuclidinyl benzilate
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Compound 71 was further tested for determining Ki to the M2 receptor. Atropine,
an M2 antagonist, was employed as a reference. The Ki of 71 was determined to be
6772 nM which is very high compared to the Ki of 1.1 nM of atropine. Therefore,
unfortunately 71 is not the best candidate to antagonize the M2 receptor.

Figure 3.18. Secondary Binding Result – M4.

Compound: 32 (40432)
Receptor: M4
Hot Ligand: [3H]QNB
Species: Human
Source: Cloned
Ki: 6,800.5 nM (average)
QNB = 3-quinuclidinyl benzilate

Similarly, the secondary binding test for M4 was done on compound 32, with
atropine as a reference again. The Ki of 32 was determined to be an average of 6,800.5
nM and this value was significantly higher than 2.5 nM of the atropine reference. Hence,
we concluded that 32 is not very specific for the M4 receptor.
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Figure 3.19. Structures of Compounds Used for M2&4 Receptors Test.

Figure 3.20. Secondary Binding Result – 5HT2B.

Compound: 48 (45250)
Receptor: 5-HT2B
Hot Ligand: [3H]LSD
Species: Human
Source: Cloned
Ki: 789 nM
LSD = lysergic acid diethylamide
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The secondary binding test of compound 48 on the 5-HT2B receptor determined
the Ki to be 789 nM, which was compared to the Ki of known 5-HT2B antagonist, SB
206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole) 96. SB
206553 96 was first reported as a drug exhibits anxiolytic properties in 1990s. 191
Although SB 206553 96 has very high affinity to 5-HT2B (18 nM), it also binds to 5-HT2C
and the α7 nicotinic acetylcholine receptor.192, 193 Even though there are no significant
side effects of SB 206553 96 reported thus far, it is still relatively new drug and there is
a possibility that adverse side effects could arise after a prolonged use, especially when
a compound binds to multiple receptors193 as this one does. Compound 48, on the other
hand, is very selective to 5-HT2B. Furthermore, compound 48 is a mixture of E and Z
isomers. Hence, because the phenyl imine group is bulky, it is likely that one isomer is
active while the other is not, or at least one is more potent than the other. Therefore,
although the Ki of 48 was significantly lower than that of the reference compound, there
is much room for improvement for 48 to acquire better efficacy.
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Figure 3.21-1. Secondary Binding Result – 5HT6.

Compound: 35 (45261)
Receptor: 5-HT6
Hot Ligand: [3H]LSD
Species: Human
Source: Cloned
Ki: 7070 nM

Compound: 47 (45249)
Receptor: 5-HT6
Hot Ligand: [3H]LSD
Species: Human
Source: Cloned
Ki: 4653 nM
LSD = lysergic acid diethylamide
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Figure 3.21-2. Secondary Binding Result – 5HT6.

Compound: 48 (45250)
Receptor: 5-HT6
Hot Ligand: [3H]LSD
Species: Human
Source: Cloned
Ki: 6780 nM

Compound: 49 (45251)
Receptor: 5-HT6
Hot Ligand: [3H]LSD
Species: Human
Source: Cloned
Ki: 3709 nM
LSD = lysergic acid diethylamide
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Figure 3.21-3. Secondary Binding Result – 5HT6.

Compound: 50 (45252)
Receptor: 5-HT6
Hot Ligand: [3H]LSD
Species: Human
Source: Cloned
Ki: 3436 nM

Compound: 65 (45258)
Receptor: 5-HT6
Hot Ligand: [3H]LSD
Species: Human
Source: Cloned
Ki: 5080 nM
LSD = lysergic acid diethylamide
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Figure 3.21-4. Secondary Binding Result – 5HT6.

Compound: 65 (45258)
Receptor: 5-HT6
Hot Ligand: [3H]LSD
Species: Human
Source: Cloned
Ki: 5080 nM

Compound: 66 (45259)
Receptor: 5-HT6
Hot Ligand: [3H]LSD
Species: Human
Source: Cloned
Ki: 3467 nM
LSD = lysergic acid diethylamide
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Figure 3.21-5. Secondary Binding Result – 5HT6.

Compound: 69 (45255)
Receptor: 5-HT6
Hot Ligand: [3H]LSD
Species: Human
Source: Cloned
Ki: 7168 nM
LSD = lysergic acid diethylamide

Eight analogs (35, 47, 48, 49, 50, 65, 66, and 69) showed affinity to 5-HT6
receptor. Clozapine 97, a 5-HT6 antagonist,195 was employed as a reference. The Ki of
each compound, ranging from 3436 nM to 7168 nM, with the reference K i in the
parentheses is as follows: 35 – 7070 nM (5.5 nM), 47 – 4653 nM (2.4 nM), 48 – 6780
nM (2.4 nM), 49 – 3709 nM (2.4 nM), 50 – 3436 nM (5.5 nM), 65 – 5080 nM (2.9 nM),
66 – 3467 nM (2.9 nM) and 69 – 7168 nM (2.9 nM). Although the lower Ki’s are still fairly
high as compared to the corresponding reference Ki’s, this information would help to
optimize further for the best fit molecule. Compounds 49 and 50 are mixtures of E-Z
isomers, and therefore, one isomer could be active and the contamination of the other
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isomer might be lowering the binding affinity. In addition, given unsubstituted aromatic
analog 66 also had relatively lower Ki, removing substituents from 49 and 50 may also
improve the binding activity

Figure 3.22. Structures of Compounds Used for 5-HT Receptors Tests.
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Figure 3.23. Secondary Binding Result – Sigma 2.

Compound: 49 (45251)
Receptor: Sigma 2
Hot Ligand: [3H]DTG
Species: Rat
Source: PC12
Ki: 8513 nM

Compound: 69 (45255)
Receptor: Sigma 2
Hot Ligand: [3H]DTG
Species: Rat
Source: PC12
Ki: 8443 nM
DTG = ditolylguanidine
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Two compounds 49 and 69 showed some affinity to the sigma 2 receptor.
Haloperidol 87 was used as a reference. The Ki of 49 was 8513 nM and that of 69 was
8443 nM, whereas the reference Ki’s were 23 nM and 32 nM, respectively. Thus,
unfortunately, neither one of them showed any significance in the affinity. However, like
the further modification suggested in 5-HT6 discussion section, separating E-Z isomers
of 49 as well as removing the substituent on the ring thereof may improve the activity.

Figure 3.24. Structures of Compounds Used for Sigma 2 Receptor Tests.
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3.5.

Summary

In summary, the physicochemical properties of our carbohydrate derivatives were
calculated to evaluate their compatibility to oral administration as well as likelihood of
them passing through the BBB. Three compounds (49, 53, and 70) have a parameter
that is out of range of good predicted permeation/oral bioavailability. However, these
molecules still can likely pass through the BBB via GLUTs, without utilizing passive
permeation. In addition, the primary binding results did not show these three to be
active on CNS receptors. Possible improvements in the physiochemical properties of
these molecules could possibly be made by considering modifications to the TPSA or
the number of H-bond acceptors.
The primary binding results revealed critically how modifications to our template
changed the properties of the derivatives. First of all, the ring conformation has to be a
half-chair. That is, the double bond on the sugar ring is a necessary factor of receptor
binding. The comparison between 32 and 35 also suggested that the location of the
double bond is also important. Second, the OH group of 12 is participating in receptor
binding as a protected alcohol derivatives 35 and 46 did not show the same activity as
12. Third, the p-methoxybenzylidene group cannot be altered or removed. The
benzylidene ring has to lie on a gluco sugar, and the substituents on the phenyl ring and
their locations definitely affect their activities on CNS receptors.
Based on the secondary binding tests and functional tests, 32 definitely has to be
modified in such a way that the Ki stays low but efficacy increases under a competitive
125

binding environment. On the other hand, 46 seems very promising as a selective
antagonist of the D3 dopamine receptor for therapeutic uses such as addiction
treatments. Toxicology studies and stability tests are necessary and will further
elucidate the potential of 46 as a therapeutic agent. Further investigation of compound
48 for 5-HT2B, including identification of the activity of isolated E/Z isomers and
functional binding test, are also interesting to pursue in the future. Likewise, separation
of E/Z isomers of 49 as well as removal of the substituent on the aromatic ring may
improve the binding affinity to 5-HT6 and/or sigma 2 receptors.
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Chapter 4

Conclusions

4.1. Conclusions

CNS disorders are chronic conditions that have great socioeconomic impact.
Despite the fact that the number of patients is drastically increasing, there is not enough
research actively being done on development of new treatments. The challenges lie
mainly along complexity of pathologies, concerns of toxicity associated with long-term
use, and difficulties in designing molecules that have high bioavailability and would pass
through the BBB. However, since a significant percentage of CNS disorder patients
have symptoms that cannot be controlled by the existing treatments, and their quality of
life is unacceptably affected, the discovery of new medications for CNS disorders is
always in high demand.
Previously, Talisman and Marzabadi synthesized a carbohydrate compound 12,
which showed anticonvulsant as well as anti-inflammatory and anti-acute pain activity.
However, the yield for the synthesis of 12 was low and there was a concern about
metabolic stability for oral administration. In addition, we were also interested in
investigating the SAR of 12 to explore the feasibility of modifications and potential
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activity changes. Therefore, the objectives of this project were: 1) to improve the yield of
the p-methoxy-benzylidenation of D-glucal leading to the formation of compound 12, 2)
to further develop the carbohydrate template and to synthesize its derivatives for
potential CNS-active drugs, and 3) to test the biological activities of the derivatives to
evaluate their potential for therapeutic uses for the treatment of various CNS disorders.
In regards to improving the yield of benzylidenation of D-glucal 16, our yield was
moderately improved due to better procedures for removing the byproduct, methanol,
favoring the equilibrium towards the product. In addition, other modifications executed
on D-glucal 16 significantly improved yields upon benzylidenation. Thus, although there
is room for further improvement, the first objective was satisfactory.
Despite the synthetic challenges, we have successfully synthesized a series of
carbohydrate compounds based on the novel carbohydrate template that was
previously developed in the group. To summarize, we have prepared deoxy pyranoses,
type I Ferrier rearrangement products, C-3 derivatives, epimers,
acetalization/ketalization derivatives and ether derivatives. Deoxy pyranoses and type I
Ferrier rearrangement derivatives were prepared in high yields and in high
stereoselectivity, and pure anomers were isolated. Modifications of the C-3 OH group
were successful and the reactions were high yielding and stereospecific. The oxidation
of the C-3 OH was optimized and a pure compound was isolated. Unfortunately, imines,
oximes and hydrazones derived from ketone derivative 46 were inseparable mixtures of
E-Z isomers. Likewise, our attempts to prepare allal derivative 58 yielded an
inseparable mixture of glucal 12 and allal 58 compounds. However, galactal 63 and
galactose 64 derivatives were successfully prepared and we were able to isolate pure
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compounds. Although the yields were very low, a number of acetalizaton/ketalization
derivatives were prepared. And lastly, ether derivatives were prepared with high
regioselectivity. Therefore, the second objective of the research was also satisfactory.
The biological testing results have revealed a range of molecules for targeting
different CNS receptors. Although many of the derivatives were not significantly active
on CNS receptors, those which were active were very selective and we have been able
to validate that small modifications of the template can alter the biological activities of
the derivatives and lead to different receptor targets. As CNS receptors often share the
same ligands, targeting a specific receptor with high selectivity is very important for
developing CNS-active molecules. In addition, because the binding pockets of various
CNS receptors are not well characterized for various ligands, the negative results can
still be beneficial to increase our understanding of the receptor site for designing better
fit molecules. With our library of molecules, we have successfully targeted different CNS
receptors. Thus, these modifications can lead to the treatment of different CNS
disorders and as such. Given the previous biological study, 12 is a privileged structure
and as a derivative of 12, 46 has shown high potential for addiction treatment,
selectively antagonizing the D3 receptor, and further investigation and optimization of
46, including in vivo and toxicology studies, will elucidate the likelihood of 46 as an
actual drug candidate. 32 requires further modification to utilize the high binding affinity
to mGluR5. Likewise, imine derivatives (47-52) need some improvements, including
separation and identification of active stereoisomers, in order to determine accurate
binding affinities and functions. Overall, our derivatives demonstrated highly selective
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CNS receptor binding, which leaves us hope of minimal side effects as compared to
many existing corresponding drugs. Hence, we have fulfilled our third objective as well.
In conclusion, we have successfully implemented the objectives of this project.
For future directions, incorporation of amines, substitution of the cyclic acetal with other
heterocycles to include nitrogen or sulfur instead of oxygen, development of purification
methods for those inseparable diastereomers, and in vivo studies of selected molecules
will be interesting. Ultimately, our novel carbohydrates have shown a great potential for
treatments of various CNS disorders, and it can be further investigated for development
of new drugs for CNS disorders.
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Chapter 5

Experimental

5.1. Experimental

General Methods:
All reactions were performed under an inert atmosphere of nitrogen (Auto Gas Light,
zero grade or Airgas, compressed nitrogen) unless otherwise specified. Liquid reagents
and solvents were transferred using an inert atmosphere using syringe techniques.
Anhydrous solvents were purchased from Aldrich Chemical Company, Sigma-Aldrich®,
Alfa Aesar®, EMD Millipore Corporation, and Honeywell Burdick & Jackson® and were
used as received unless otherwise specified. Other solvents were purchased from
Macron Fine ChemicalsTM and Mallinckrodt Chemical and were used as received unless
otherwise specified. Dichloromethane was used as received from Macron Fine
ChemicalsTM or was freshly distilled from calcium hydride. Other chemicals were
purchased from Alfa Aesar®, Sigma-Aldrich®, TCITM, Acros Organics, Oakwood
Chemical and Carbosynth and were used as received unless otherwise mentioned.
Flash chromatography was performed on silica gel (SilicaFlash® P60, 230 – 400 mesh)
from SiliCycle Inc. Analytical TLC plates (silica gel F coated on Aluminum foil, 20 x 20
cm, 200 microns) and Preparative TLC plates (silica gel GF on glass, 20 x 20 cm, 2000
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microns) were purchased from Analtech and were conditioned with triethylamine prior to
use as necessary. Molecular sieves (4Å, 3-5 mm beads) and sand (washed SiO2) were
purchased from Alfa Aesar®, and Celite® 545 was purchased from EMD Chemicals,
Inc. and were used as received unless otherwise specified. Melting points (mp) were
determined in open capillary tubes on a Mel-Temp apparatus and the values are
corrected according to the observed mp of benzoic acid (mp = 122.4 0C). Specific
optical rotations ([α]) were measured with DigiPol 781 Automatic Polarimeter by
Rudolph Instruments, Inc. (Fairfield, New Jersey, U.S.A.) at a wavelength of 589 nm
supplied by sodium lamp. 1H, 13C, gCOSY and gHMQC NMR spectra were acquired on
a Varian Inova AS500 (500 MHz) spectrometer in chloroform-d, methanol-d4,
acetonitrile-d3 (all from Cambridge Isotope Laboratories Inc.), or acetone-d6 (Alfa
Aesar®) with tetramethylsilane as the internal standard (reference set as 0.0 ppm for 1H
and 13C NMR) for selected solvents. 19F NMR was acquired on Varian Inova (400 MHz).
NMR data obtained was processed with ACD/NMR Processor Academic Edition ver.
12.01 by Advanced Chemistry Development. Chemical shifts (δ) are expressed in ppm,
coupling constants (J) are expressed in Hz, and splitting patterns are described as
follows: s = singlet; d = doublet; t = triplet, q = quartet; dd = doublet of doublets; dt =
doublet of triplets; td = triplet of doublets; ddd = doublet of doublet of doublets; m =
multiplet. Elemental analysis was performed by Robertson Microlit Laboratories, Inc.
(Madison, NJ). Fourier transform infrared spectroscopy (FTIR) was performed on a
NaCl plate with a Nicolet 4700 FT-IR and the obtained data was processed with OMNIC
7.1, both by Thermo Electron Corporation. High resolution mass spectra were obtained
from the mass spectrometry laboratory, University of Illinois at Urbana-Champaign,
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School of Chemical Science (Urbana, IL) using electrospray ionization (ESI), and are
reported as [M+H]+ or [M+Na]+.Compounds 23196, 26197, 34198, 35199, 69200, 71201, and
73136 were prepared as described in the literature using inert atmosphere conditions,
with oven-dried glassware and the spectral characteristics thereof were analyzed and
were determined to be consistent with literature values.

Receptor Binding Profiles:
Screening for in vitro binding and activities against various CNS-receptors and
transporters was generously provided by the National Institute of Mental Health's
Psychoactive Drug Screening Program, Contract # HHSN-271-2013-00017-C (NIMH
PDSP). The NIMH PDSP is directed by Bryan L. Roth MD, PhD at the University of
North Carolina at Chapel Hill and project officer Jamie Driscoll at NIMH, Bethesda MD,
USA. Protocols for receptor-based assays by the PDSP may be found on their website
at: https://pdspdb.unc.edu/pdspWeb/ and
https://pdspdb.unc.edu/pdspWeb/content/PDSP%20Protocols%20II%202013-03-28.pdf
(cited on February 22nd, 2017).
The primary binding results against over 50 CNS receptors and transporters are
reported as a mean % inhibition with N = 4 determinations, using the default
concentration of 10 µM. Over 50% inhibition is considered as a significant inhibition. The
secondary binding tests are performed in order to determine the binding affinity, the Ki
values (nM), calculated from IC50, using the Cheng-Prusoff equation. The secondary
binding test is non-competitive binding and the affinity was measured as a function of
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decreased hot ligand binding. The primary functional tests were performed at 10 µM
with a presence of the 50% effective dose (EC50) concentrations of a typical agonist, to
determine the agonizing/antagonizing activity of the compound. The secondary
functional tests were performed to determine whether agonizing or antagonizing activity
is present, as well as, to determine IC50 values under competitive binding conditions,
when feasible.

Physicochemical properties:
Physicochemical properties of all compounds were calculated with ChemDraw®
professional, version 16.0.0.82 (68) and Chem3D® Pro, version 16.0.0.82, by
PerkinElmer Informatics, Inc. The parameters determined were molecular weight, heavy
atom counts, rotatable bonds, number of H-bond acceptors, number of H-bond donors,
partition coefficient (cLogP), total polar surface area (TPSA) and pK a.
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Preparation of p-dichloromethylanisole (18):
To a solution of p-anisaldehyde 17 (2.42 mL, 20.0 mmol) in freshly distilled hexanes
(100 mL) was added 1.0 M solution in hexanes of boron trichloride (20 mL, 20.0 mmol)
at room temperature under N2 environment. The solution was refluxed for 8 hours and
then was cooled down to room temperature. The reaction solution was washed with D.I.
water (3 x 50 mL) then with brine (150 mL). It was dried over Na2SO4. The dried organic
layer was concentrated in vacuo to afford crude product as a clear, viscous liquid that
was subjected to chromatographic purification (SiO2, 30 % EtOAc in hexanes) to yield a
clear, viscous liquid of pure product 18 (1.94 g, 10.2 mmol) in 51% yield. 1H NMR (500
MHz, CDCl3) δ7.49 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 6.69 (s, 1H), 3.81 (s,
3H); 13C (125 Hz, CDCl3) δ160.6, 132.8, 127.5, 114.0, 71.7, 55.4.
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Preparation of (2R,4aR,6S,8aS)-6-methoxy-2-(4-methoxyphenyl)-4,4a,6,8atetrahydropyrano[3,2-d][1,3]dioxine (29):
To a solution of 16 (0.44 g, 3.0 mmol) in p-anisaldehyde dimethylacetal (7.7 mL, 45.0
mmol) was added p-toluenesulfonic acid (0.06 g, 0.3 mmol). The reaction was stirred at
room temperature under a N2 environment for 15 min. The reaction was diluted with
DCM (10 mL), washed with saturated NaHCO3 solution (10 mL) followed by H2O (10
mL). The organic layer was washed with brine (10 mL) followed by MgSO4. The dried,
organic layer was concentrated in vacuo and the resulting crude was purified by column
chromatography (SiO2, gradient from pure to a 1:4 mixture of ethyl acetate in hexanes)
to afford a white solid (0.56 g, 2.0 mmol, 68% yield): mp = 117-118 0C. [α]D24 +68 (c 0.3,
CH2Cl2). 1H NMR ((CD3)2CO, 500 MHz) δ7.40 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 8.3 Hz,
2H), 6.18 (d, J = 10.3 Hz, 1H), 5.73 (dd, J = 2.4, 7.1 Hz, 1H), 5.61 (s, 1H), 4.91
(apparent s, 1H), 4.18 (dd, J = 4.9, 20.3 Hz, 1H), 4.15 (apparent d, 8.8 Hz, 1H), 3.79 (m,
4H), 3.71 (apparent dt, J = 4.4, 10.0 Hz, 1H), 3.40 (s, 3H); 13C NMR ((CD3)2CO, 125
MHz) δ161.0, 131.5, 131.2, 128.5, 128.0, 114.1, 102.6, 96.9, 75.8, 69.8, 65.1, 55.9,
55.5. HRMS (m/z): [M+Na]+ Calcd. for C15H18O5Na, 301.1052; Found 301.1049 (∆ 0.3
mmu).
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Preparation of (2R,4aR,8aS)-2-(4-methoxyphenyl)-4,4a,6,8a-tetrahydropyrano[3,2d][1,3]dioxine (32):
To a solution of 31 (1.37 g, 10.5 mmol) and p-anisaldehyde dimethylacetal (3.6 mL,
21.0 mmol) in anhydrous DMF (10 mL) was added p-toluenesulfonic acid (0.20 g, 1.1
mmol). The reaction was conducted under reduced pressure at 40 0C for 3 hours. The
reaction was then cooled down to room temperature, diluted with DCM (15 mL), washed
with saturated NaHCO3 solution (15 mL), H2O (3 x 15 mL) and brine (15 mL). The
organic layer was dried over Na2SO4 and concentrated in vacuo to afford a crude
mixture, which was subjected to chromatographic purification (SiO2, a gradient of pure
hexane to a 1:4 mixture of ethyl acetate in hexanes) to give 32 as a needle-shaped
white solid (1.58 g, 6.4 mmol, 61% yield): mp = 96-98 0C. 1H NMR ((CD3)2CO, 500
MHz) δ7.40 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 9.2 Hz, 2H), 5.88 (dd, J = 2.0, 12.7 Hz, 1H),
5.82 (dd, J = 2.5, 10.5 Hz, 1H), 5.61 (s, 1H), 4.32-4.27 (m, 1H), 4.23-4.16 (m, 3H), 3.79
(s, 3H), 3.73 (apparent t, 10.3 Hz, 1H), 3.40 (ddd, J = 2.0, 4.7, 13.7 Hz, 1H); 13C NMR
((CD3)2CO, 125 MHz) δ160.9, 131.6, 128.7,128.5, 126.9, 114.1, 114.0, 102.4, 75.9,
71.4, 66.9, 55.5. HRMS (m/z): [M+Na]+ Calcd. for C14H16O4Na, 271.0946; Found
271.0954 (∆ 0.8 mmu).
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Preparation of (2R,4aR,8R,8aS)-2-(4-methoxyphenyl)-4,4a,8,8a-tetrahydropyrano[3,2d][1,3]dioxin-8-yl acetate (33):
To a solution of 12 (0.11 g, 0.43 mmol) in anhydrous pyridine (0.35 mL) was added
drop-wise acetic anhydride (0.4 mL, 4.27 mmol). The reaction was stirred at room
temperature under a N2 environment for 1 hour. H2O (1 mL) was added to the reaction
and the solution was concentrated in vacuo. The residue was redissolved in DCM (20
mL), washed with H2O (2 x 20 mL) and the organic layer was dried over MgSO4. The
dried organic layer was concentrated in vacuo and the crude was purified with a
preparative TLC (SiO2, a 1:1 ratio of ethyl acetate to hexanes) to afford a white solid
(0.10 g, 0.33 mmol, 78% yield): mp = 117-118 0C. [α]D23 -11 (c 0.4, CH2Cl2). 1H NMR
((CD3)2CO, 500 MHz): δ7.40 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 8.8 Hz, 2H), 6.49 (dd, J =
1.5, 5.9 Hz, 1H), 5.67 (s, 1H), 5.47 (dd, J = 2.0, 9.8 Hz, 1H), 4.76 (dd, J = 2.0, 6.4 Hz,
1H),4.31 (dd, J = 4.9, 10.3 Hz, 1H), 4.06 (apparent t, J = 10.3 Hz, 1H), 3.99 (apparent
dt, J = 4.9, 10.0 Hz, 1H) 3.87 (apparent t, J = 10.3 Hz, 1H), 3.79 (s, 3H), 2.01 (s, 3H);
13C

NMR ((CD3)2CO, 125 MHz) δ171.4, 161.7, 146.8, 131.6, 129.1, 114.7, 102.7, 102.1,

78.0, 69.9, 69.1, 56.1, 21.5. HRMS (m/z): [M+H]+ Calcd. for C16H19O6, 307.1182; Found
307.1187 (∆ 0.5 mmu).
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Preparation of (2R,4aR,8aR)-2-(4-methoxyphenyl)-4a,8a-dihydropyrano[3,2d][1,3]dioxin-8(4H)-one (46):
To a solution of 12 (0.26 g, 1.0 mmol) in freshly distilled DCM (5 mL) with molecular
sieves was added pyridinium chlorochromate (0.43 g, 2.0 mmol) at room temperature.
The reaction was conducted under a N2 environment for 2 hours and disappearance of
starting material was confirmed with TLC. The reaction mixture was filtered through a
pad of silica gel, using a vacuum filtration apparatus and the silica gel was washed with
DCM. The filtrate was discarded and the product adsorbed onto the silica gel was then
washed with excess ethyl acetate. The ethyl acetate filtrate was concentrated in vacuo
to afford a white solid (0.21 g, 0.8 mmol, 79% yield): mp = 121-123 0C. [α]D22 +148 (c
0.6, CH2Cl2). 1H NMR ((CD3)2 CO, 500 MHz) δ7.51 (d, J = 5.9 Hz), 7.42 (d, J = 8.3 Hz,
2H), 6.93 (d, J = 8.8 HZ, 2H), 5.68 (s, 1H), 5.36 (d, J = 6.4 Hz, 1H), 4.63 (d, J = 12.2 Hz,
1H), 4.44 – 4.36 (m, 2H), 4.10 (apparent t, J = 9.8 Hz, 1H), 3.80 (s, 3H); 13C NMR
( (CD3)2 CO, 125 MHz) δ188.5, 162.4, 161.2, 130.7, 128.6, 114.2, 106.6, 102.3, 78.0,
74.1, 68.2, 55.6. HRMS (m/z): [M+H]+ Calcd. for C14H15O5, 263.0919; Found 263.0927
(∆ 0.8 mmu).
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General procedure for the preparation of compounds 47, 48, 49, and 50:
To a solution of 46 (0.13 g, 0.5 mmol) in methanol (5 mL) was added amine (1 mmol).
The reaction was stirred at room temperature for 2-12 hours. The reaction was
quenched by removing the excess amine (if volatile) and the solvent was removed in
vacuo. The crude product was purified by column chromatography.

(2R,4aR,8aS,E/Z)-2-(4-methoxyphenyl)-4a,8a-dihydropyrano[3,2-d][1,3]dioxin-8(4H)imine (47):
Compound 46 (0.13 g, 0.5 mmol) was dissolved in methanol (5 mL) and 2.0 M solution
of ammonia in methanol (0.5 mL, 1 mmol) was added. The crude mixture obtained was
purified by column chromatography (SiO2, a 1:1 ratio of ethyl acetate to hexanes) and
produced a yellow solid (0.06 g, 0.17 mmol, 33%) as a mixture of E-Z isomers. 1H NMR
((CD3)2CO, 500 MHz): δ7.43 (d, J = 8.8 Hz, 2H), 7.23 – 7.17 (m, 1H), 6.93 (d, J = 8.8
Hz, 2H), 5.59 (s, 1H), 5.44 (apparent dt, J = 1.5, 7.4 Hz, 1H), 4.18 (dd, J = 5.4, 10.5 Hz,
1H), 3.96 (d, J = 8.8 Hz, 1H), 3.80 (s, 3H), 3.78 – 3.75 (m, 1H), 3.60 (apparent t, J =
10.3 Hz, 1H); 13C NMR ((CD3)2CO, 125 MHz) δ198.3, 154.3, 131.6, 128.5, 114.1, 101.7,
90.5, 83.3, 81.8, 74.1, 71.5, 66.1, 55.6, 34.8. FTIR (NaCl): 3400, 2958, 2957, 2854,
1734, 1640, 1514, 1251, 1086, 1030 cm-1. HRMS (m/z): [M+H]+ Calcd. for C14H16NO4,
262.1079; Found 262.1077 (∆ 0.2 mmu).
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(2R,4aR,8aS,E/Z)-2-(4-methoxyphenyl)-N-phenyl-4a,8a-dihydropyrano[3,2d][1,3]dioxin-8(4H)-imine (48):
Treatment of 46 (0.13 g, 0.5 mmol) solution in methanol (5 mL) with aniline (0.09 mL, 1
mmol) yielded a crude mixture. Column chromatography (SiO2, a 1:1 ratio of ethyl
acetate to hexanes) yielded a yellow solid (0.07 g, 0.20 mmol, 39%) as a mixture of E-Z
isomers.1H NMR ((CD3)2CO, 500 MHz) δ7.79 (dd, J = 7.8, 12.7 Hz, 1H), 7.45 (d, J = 8.8
Hz, 2H), 7.39 (t, J = 8.8 HZ, 2H), 7.28 (d, J = 7.8 Hz, 2H), 7.12 (t, J = 7.3 Hz, 1H), 6.94
(d, J = 8.8 Hz, 2H), 5.74 (d, J = 7.8 Hz, 1H), 5.62 (s, 1H), 4.22 (dd, J = 4.9, 10.5 Hz,
1H), 4.09 (d, J = 9.3 Hz, 1H), 3.88 – 3.84 (m, 1H), 3.81 (s, 3H), 3.65 (apparent t, J =
10.8 Hz, 1H); 13C NMR ((CD3)2CO, 125 MHz) δ198.6, 161.0, 147.0, 140.9, 131.5, 130.7,
128.5, 124.8, 124.0, 121.5, 117.2, 114.1, 111.7, 102.3, 101.6, 93.8, 87.6, 84.2, 71.5,
65.0, 55.6. FTIR (NaCl): 3416, 3236, 2955, 2923, 2847, 1640, 1552, 1248, 1213, 1094,
1034, 987, 833, 758, 690 cm-1. HRMS (m/z): [M+H]+ Calcd. for C20H20NO4, 338.1392;
Found 338.1382 (∆ 0.1 mmu).
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2-(((2R,4aR,8aS,E/Z)-2-(4-methoxyphenyl)-4a,8a-dihydropyrano[3,2-d][1,3]dioxin8(4H)-ylidene)amino)ethan-1-amine (49):
Treatment of 46 (0.13 g, 0.5 mmol) in methanol (5 mL) with ethylenediamine (0.07 mL,
1 mmol) afforded crude product. Column chromatography (SiO2, hexanes-ethyl acetate
= 1:1) yielded a white solid 49 (0.10 g, 0.34 mmol, 68%) as a mixture of E-Z isomers. 1H
NMR (CD3CN, 500 MHz) δ7.88 (d, J = 11.75, 1H), 7.40 (d, J = 8.3 Hz, 2H), 6.92 (d, J =
8.8 Hz, 2H), 5.55 (s, 1H), 5.34 – 5.30 (br m, 1H), 4.18 (dd, J = 5.35, 10.5 Hz, 1H), 3.94
– 3.91 (br m, 1H), 3.79 (s, 3H), 3.77 – 3.75 (br m, 1H), 3.58 (apparent t, J = 10.25, 1H),
3.22 (t, J = 6.4 Hz, 2H), 3.13 (t, J = 6.9 Hz, 2H); 13C NMR (CD3CN, 125 MHz) δ201.9,
161. 4, 137.9, 131.9, 128.9, 114.7, 102.2, 102.0, 83.8, 71.9, 65.8, 56.3, 49.0, 43.8. FTIR
(NaCl): 3411, 2962, 2920, 2844, 1631, 1553, 1492, 1458, 1391, 1249, 1980, 1031,
1002, 627 cm-1. HRMS (m/z): [M+H]+ Calcd. for C20H21N2O4, 305.1501; Found 305.1492
(∆ 0.9 mmu).
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(2R,4aR,8aS,E/Z)-2-(4-methoxyphenyl)-N-propyl-4a,8a-dihydropyrano[3,2-d][1,3]dioxin8(4H)-imine (50):
Treatment of 46 (0.13 g, 0.5 mmol) in methanol (5 mL) with ethylenediamine (0.08 mL,
1 mmol) yielded a crude mixture. Column chromatography (SiO2, hexanes-ethyl acetate
= 1:1) gave a white solid (0.09 g, 0.30 mmol, 59%) as a mixture of E-Z isomers. 1H
NMR ((CD3)2CO, 500 MHz) δ7.42 (d, J = 8.8 Hz, 2H), 7.15 (dd, J = 7.3, 13.2 HZ, 1H),
6.92 (d, 8.8 Hz, 2H) 5.58 (s, 1H), 5.37 (dd, J = 1.5, 4.8 Hz, 1H), 4.17 (dd, J = 4.9, 10.5
Hz, 1H), 3.95 (d, J = 9.3 Hz, 1H), 3.80 (s, 3H), 3.59 (apparent t, J = 10.3 Hz, 2H), 3.31
(t, J = 6.4 Hz, 2H), 1.62 (q, J = 7.4 Hz, 2H), 0.94 (t, J = 7.4 Hz, 3H); 13C NMR
((CD3)2CO, 125 MHz) δ197.2, 161.3, 157.1, 157.0, 132.0, 128.8, 114.4, 102.1, 102.0,
83.2, 71.8, 65.9, 55.9, 51.3, 25.3, 11.5. FTIR (NaCl): 3381, 2963, 2932, 2874, 1640,
1631, 1549, 1519, 1463, 1390, 1250, 1173, 1135, 1084, 1032, 832, 739 cm -1. HRMS
(m/z): [M+H]+ Calcd. for C17H21NO4, 304.1549; Found 305.1546 (∆ 0.3 mmu).
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General procedure for preparation of compounds 51 and 52:
Amine hydrochloride salt (0.5 mmol,) was dissolved in methanol (5 mL) and sodium
hydroxide (20 mg, 0.5 mmol) was added. The mixture was stirred for 1 hour to
neutralize the HCl salt and 46 (0.13 g, 0.5 mmol) was added. The reaction was stirred
for an additional 12 hours. The solvent was evaporated in vacuo and the residue was
re-dissolved in DCM (10 mL). The solution was washed with H2O (3 x 5 mL) followed by
brine (10 mL) and was dried over sodium sulfate. The drying agent was filtered out and
the organic phase was concentrated in vacuo.
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(2R,4aR,8aS,E/Z)-2-(4-methoxyphenyl)-4a,8a-dihydropyrano[3,2-d][1,3]dioxin-8(4H)one oxime (51):
A treatment of 46 (oxidized benzylidene) (0.13 g, 0.5 mmol) with neutralized
hydroxylamine hydrochloride (0.03 g, 0.5 mmol) in methanol formed a cloudy solution.
Workup yielded a crude mixture which was subject to purification. Column
chromatography (SiO2, a 1:1 ratio of ethyl acetate to hexanes) yielded a white solid
(0.09 g, 0.32 mmol, 56%) as a mixture of E-Z isomers (major to minor = 1:0.3, by NMR).
1H

NMR ((CD3)2CO, 500 MHz) δ7.40 (d, J = 8.3 Hz, 2H), 6.90 (d, J = 8.3 Hz, 2H), 6.06

(apparent s, 1H), 5.63 (s, 1H), 5.16 (apparent s, 1H), 4.52 (d, J = 9.3 Hz, 1H), 4.27 (dd,
J = 5.4, 11.0 Hz, 1H), 3.98 – 3.92 (m, 1H), 3.86 (apparent dt, J = 4.9, 9.5 Hz, 1H), 3.78
(s, 3H), 3.70 (apparent t, J = 10.7, 1H) ; 13C NMR ((CD3)2CO, 125 MHz) δ171.5, 164.8,
161.2, 160.4, 131.8, 128.8, 114.3, 104.3, 102.0, 101.9, 78.6, 77.8, 77.7, 72.1, 65.5,
55.8. FTIR (NaCl): 3379, 3259, 3142, 2965, 2898, 2851, 2834, 1638, 1613, 1572, 1518,
1501, 1458, 1385, 1298, 1248, 1175, 1089, 1033, 1017, 983, 831, 816 cm -1. HRMS
(m/z): [M+Na]+ Calcd. for C14H15NO5Na, 300.0848; Found 300.0843 (∆ 0.5 mmu).
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(2R,4aR,8aS,E/Z)-2-(4-methoxyphenyl)-4a,8a-dihydropyrano[3,2-d][1,3]dioxin-8(4H)one O-methyl oxime (52):
A treatment of 46 (0.13 g, 0.5 mmol) with neutralized methoxyamine hydrochloride (0.04
g, 0.5 mmol) in methanol resulted in the formation of a precipitate. The workup yielded a
crude mixture which was subject to purification. Column chromatography (SiO2, a 1:1
ratio of ethyl acetate to hexanes) yielded a white solid (0.09 g, 0.32 mmol, 63%) as a
mixture of E-Z isomers. 1H NMR (CD3OD, 500 MHz) δ7.41 (d, J = 8.8 Hz, 2H), 7.38 (d,
J = 8.8 Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 6.05 (s, 1H), 5.14 (d, 3.4 Hz, 1H), 4.58 (dd, J =
2.5, 9.8 Hz, 1H), 4.06 (dd, J = 3.0, 12.7 Hz, 1H), 4.00 – 3.94 (m, 1H), 3.87 (s, 3H), 3.82
(s, 3H), 3.61 – 3.56 (m, 1H); 13C NMR ((CD3)2CO, 125 MHz) δ161.3, 153.3, 150.7,
129.5, 115.3, 114.6, 103.1, 101.6, 100.6, 97.3, 70.3, 69.2, 60.3, 56.1. FTIR (NaCl):
2974, 2935, 2895, 2870, 1614, 1518, 1463, 1378, 1303, 1250, 1171, 1133, 1096, 1036,
978, 935, 828, 785 cm-1. HRMS (m/z): [M+H]+ Calcd. for C15H18NO5, 292.1185; Found
292.1185 (∆ 0.0 mmu).
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General procedure for preparation of compounds 53 and 54:
To a solution of 46 (0.09 g, 0.35 mmol) in THF (3.0 mL) was added hydrazine or
phenylhydrazine (14.0 mmol). The reaction was stirred at room temperature for 2 hours.
It was quenched by evaporating solvent in vacuo and the crude mixture was purified by
a column chromatography.

(E/Z)-((2R,4aR,8aS)-2-(4-methoxyphenyl)-4a,8a-dihydropyrano[3,2-d][1,3]dioxin-8(4H)ylidene)hydrazine (53):
Treatment of 46 (0.09 g, 0.35 mmol) with hydrazine (0.8 mL of 40% aq. Solution, 14.0
mmol) followed by workup afforded a crude mixture. Column chromatography (SiO 2, a
1:4 ratio of hexanes in ethyl acetate) yielded E/Z mixture of yellow solids (0.05 g, 0.16
mmol, 48%). 1H NMR (CD3OD, 500 MHz) δ7.60 (br. s, 1H), 7.41 (d, J = 8.3 Hz, 2H),
6.88 (d, J = 8.8, 1H), 6.43 (apparent d, J = 1.5 Hz, 1H), 5.63 (s, 1H), 4.77 (apparent d, J
= 9.3 Hz, 1H), 4.29 (dd, J = 4.9, 10.1 Hz, 1H), 3.92 (br. S, 1H), 3.77 (s, 3H), 3.71
(apparent t, J = 10.1 Hz, 1H); 13C NMR (CD3OD, 125 MHz) δ161.5, 131.5, 128.8, 128.7,
114.5, 114.4, 104.9, 102.7, 80.0, 72.5, 66.2, 55.8, 55.7. FTIR (NaCl): 3585, 2924, 2854,
1742, 1613, 1514, 1462, 1372, 1264, 1242, 1177, 1116, 1080, 1016, 979, 817, 742 cm1.

HRMS (m/z): [M+Na]+ Calcd. for C14H16N2O4Na, 299.1008; Found 299.1007 (∆ 0.1

mmu).
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(E/Z)-1-((2R,4aR,8aS)-2-(4-methoxyphenyl)-4a,8a-dihydropyrano[3,2-d][1,3]dioxin8(4H)-ylidene)-2-phenylhydrazine (54):
Treatment of 46 (0.09 g, 0.35 mmol) with phenylhydrazine (1.4 mL, 14.0 mmol) followed
by workup afforded a crude mixture. Column chromatography (SiO2, a 1:4 ratio of
hexanes in ethyl acetate) yielded a yellow solid (0.05 g, 0.14 mmol, 42%). 1H NMR
((CD3)2CO, 500 MHz) δ8.31 (d, 2.5 Hz, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.50 (t, J = 7.3 Hz,
2H), 7.44 (d, J = 8.3 Hz, 2H), 7.31 (t, 7.3 Hz, 1H), 6.91 (d, J = 8.8 Hz, 2H), 6.61 (d, J =
2.5 Hz, 1H), 5.71 (s, 1H), 4.75 (d, J = 9.3 Hz, 1H), 4.37 – 4.30 (m, 2H), 4.05 (d, J = 7.4
Hz, 1H), 3.79 (s, 3H); 13C NMR ((CD3)2CO, 125 MHz) δ160.9, 153.5, 141.0, 131.8,
130.3, 128.5, 127.0, 119.4, 114.1, 114.0, 110.8, 107.2, 101.8, 79.9, 72.0, 65.8, 61.5,
55.5. FTIR (NaCl): 3386, 3145, 3057, 2952, 2950, 2854,1743, 1710, 1600, 1518, 1502,
1462, 1384, 1302, 1250, 1173, 1080, 1032, 831, 757, 692. HRMS (m/z): [M+H]+ Calcd.
for C20H21N2O4, 353.1501; Found 353.1505 (∆ 0.4 mmu).
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Preparation of (2R,4aR,8S,8aS)-2-(4-methoxyphenyl)-4,4a,8,8a-tetrahydropyrano[3,2d][1,3]dioxin-8-ol (58):
A solution of 46 (0.13 g, 0.5 mmol) in ethanol (5 mL) was cooled down to 0 0C. Sodium
borohydride (0.04 g, 1.0 mmol) was added to the solution and the reaction was stirred at
0 0C for 2 hours. A saturated aqueous solution of NH4Cl was added to the reaction and
the product was extracted with DCM (3 x 15 mL). The combined organic layer was dried
over MgSO4 and concentrated in vacuo. The resulting crude product was purified by a
column chromatography to afford a mixture of 12 and 58 as white solids (0.12 g, 0.45
mmol, 91% yield). The ratio of 12 to 58 was determined by 1H NMR to be 4:1. 1H NMR
((CD3)2 CO, 500 MHz) δ7.45 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 6.45 (d, J =
6.4 Hz, 1H), 5.70 (s, 1H), 4.98 (apparent t, J = 5.9 Hz, 1H), 4.38 (apparent t, J = 4.9 Hz,
1H), 4.22 (apparent t, J = 3.9 Hz, 1H), 4.14 (apparent dt, J = 5.4, 10.5 Hz, 1H), 3.87 (d,
J = 3.9 Hz, 1H), 3.83 (s, 3H), 3.78 – 3.76 (m, 1H); 13C NMR ((CD3)2 CO, 125 MHz)
δ161.0, 144.0, 131.4, 128.5, 114.0, 106.2, 102.2, 81.6, 69.6, 68.7, 64.8, 55.5: HRMS
(m/z): [M+Na]+ Calcd. for C14H16O5Na, 287.0895; Found 287.0894 (∆ 0.1 mmu).
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Preparation of compoounds 63 and 64:
A solution of 62 (0.73 g, 5 mmol) in anhydrous DMF/Toluene (1:1 v/v, 15 mL) was
concentrated in vacuo at 50 0C for 1 hour to remove any residual water. To the solution
of 62 were added p-anisaldehyde dimethylacetal (1.3 mL, 7.5 mmol) and ptoluenesulfonic acid (0.19 g, 1 mmol). The reaction was conducted at 40 0C under
reduced pressure for 2 hours. The reaction was cooled to room temperature and was
diluted with 15 mL of DCM. The reaction was quenched by washing with 10 mL of
saturated aqueous NaHCO3 solution followed by 3 x 10 mL of deionized water. The
organic layer was dried over MgSO4 and concentrated in vacuo to afford a crude
mixture. Column chromatography (SiO2, a 1:1 ratio of ethyl acetate to hexanes) on the
mixture afforded the major product of 63 as a white solid (0.52 g, 2.0 mmol) 40% yield),
and the minor product of 64 as a white solid (0.15 g, 0.5 mmol,10% yield), total in 50%
yield. The isolated ratio of 63 to 64 was 4:1.
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(2S,4aR,8R,8aR)-2-(4-methoxyphenyl)-4,4a,8,8a-tetrahydropyrano[3,2-d][1,3]dioxin-8-ol
(63): mp = 84-85 0C. [α]D22 +16 (c 0.1, CH2Cl2). 1H NMR ((CD3)2 CO, 500 MHz) δ7.40
(d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 6.71, (d, J = 6.4 Hz, 1H), 5.88 (s, 1H), 5.03
(dd, J = 2.9, 6.4 Hz, 1H), 4.77 (ddd, J = 0.5, 3.2, 6.2 Hz, 1H), 4.50 (apparent d, J = 6.4
Hz, 1H), 3.95 (apparent t, 6.4 Hz, 1H), 3.80 (s, 3H), 3.79-3.76 (m, 2H); 13C NMR ((CD3)2
CO, 125 MHz) δ162.0, 149.6, 131.9, 129.7, 114.8, 103.3, 101.0, 78.1, 74.2, 71.0, 63.1,
56.1 HRMS (m/z): [M+Na]+ Calcd. for C14H16O5Na, 287.0895; Found 287.0894 (∆ 0.1
mmu).

(2S,4aR,6S,8R,8aR)-6-methoxy-2-(4-methoxyphenyl)hexahydropyrano[3,2d][1,3]dioxin-8-ol (64): mp = 129-130 0C. [α]D23 +112 (c 0.5, CH2Cl2). 1H NMR ((CD3)2
CO, 500 MHz) δ7.44 (d, J = 8.3 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 5.58 (s, 1H), 4.85 (d,
J = 2.5 Hz, 1H), 4.13 – 4.06 (m, 3H), 4.02 – 3.98 (m, 1H),3.80 (s, 3H), 3.59 (d, J = 1.5
Hz), 3.31 (s, 3H), 1.96 (apparent dt, J = 3.5, 12.2 Hz, 1H), 1.78 (dd, J = 4.9, 12.7 Hz,
1H); 13C NMR ((CD3)2 CO, 125 MHz) δ160.8, 132.6, 128.5, 114.0, 101.2, 100.1, 76.3,
70.4, 64.8, 63.8, 54.9, 34.3. HRMS (m/z): [M+H]+ Calcd. for C15H21O6, 297.1338; Found
297.1328 (∆ 1.0 mmu).
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General procedure for the preparation of compounds 65, 67 and 69:
A solution of 16 (0.5 g, 2.2 mmol) in DMF/Toluene (1:1 v/v, 5.0 mL) was concentrated in
vacuo at 50 0C for 1 hour to remove residual water. To the solution were added
aldehyde or aldehyde dimethylacetal (15 mmol) and a catalytic amount of ptoluenesulfonic acid to adjust the pH to ~3. The reaction was conducted at 40-50 0C
under reduced pressure for 2 hours. The reaction was cooled to room temperature and
was diluted with 25 mL of DCM. The reaction was quenched by washing with 20 mL of
saturated aqueous NaHCO3 solution followed by 3 x 20 mL of deionized water. The
organic layer was dried over MgSO4 and concentrated in vacuo. The crude compound
was subject to a purification by a flash column chromatography to afford a white powder
of pure product.
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General procedure for preparation of compounds 66, 68 and 70:
To a solution of 16 (0.5 g, 2.2 mmol) in aldehyde (2.0 mL) was added freshly fused
ZnCl2 (0.06 g, 0.44 mmol) and the mixture was stirred at room temperature for 2 to 5
hours.

(2R,4aR,8S,8aS)-2-(2-methoxyphenyl)-4,4a,8,8a-tetrahydropyrano[3,2-d][1,3]dioxin-8-ol
(65):
Treatment of 16 (0.5 g, 2.2 mmol) with o-anisaldehyde (0.4 g, 3.3 mmol) and
p-toluenesulfonic acid (20.9 mg, 0.11 mmol) in DMF-toluene yielded a crude mixture.
Column chromatography (SiO2, a 1:1 ratio of ethyl acetate to hexanes) afforded a white
solid (0.03 g, 0.1 mmol) 6% yield: mp = 119-121 0C. [α]D23 -11 (c 0.02, CH2Cl2). 1H NMR
((CD3)2CO, 500 MHz) δ7.55 (d, J = 7.3 Hz, 1H), 3.35 (t, J = 6.8 Hz, 1H), 7.02 (d, J = 8.3
Hz, 1H), 6.97 (t, J = 7.8 Hz, 1H), 6.36 (dd, J = 1.5, 6.6 Hz, 1H), 5.97 (s, 1H), 4.74 (dd, J
= 2.0, 6.4 Hz, 1H), 4.36 (gd, J = 7.3 Hz, 1H), 4.24 (dd, J = 4.4, 9.8 Hz, 1H), 3.85 (s, 3H),
3.83 – 3.72 (m, 3H); 13C NMR ((CD3)2 CO, 125 MHz) δ157.5, 144.0, 140.7, 131.0,
128.3, 121.0, 111.7, 106.2, 97.5, 81.9, 69.8, 68.9, 66.7, 56.0. HRMS (m/z): [M+Na] +
Calcd. for C14H16O5Na, 287.0895; Found 287.0887 (∆ 0.8 mmu).
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(2R,4aR,8S,8aS)-2-(3-methoxyphenyl)-4,4a,8,8a-tetrahydropyrano[3,2-d][1,3]dioxin-8-ol
(66):
Treatment of 16 (0.5 g, 2.2 mmol) with m-anisaldehyde (0.40 mL, 3.3 mmol) and ZnCl2
(0.06 g, 0.44 mmol) yielded a crude mixture. Column chromatography (SiO2, a 1:1 of
ethyl acetate to hexanes) afforded a white solid (0.16 g, 0.6 mmol, 28% yield): mp =
104-107 0C. [α]D23 +15 (c 0.3, CH2Cl2). 1H NMR ((CD3)2CO, 500 MHz) δ7.31 – 7.27 (m,
2H), 7.07 (s, 1H), 6.93 (dd, J = 2.5, 8.1 Hz, 1H), 6.36 (dd, J = 2.0, 6.1 Hz, 1H), 5.65 (s,
1H), 4.75 (dd, J = 2.0, 5.9 Hz, 1H), 4.39 (apparent dt, J = 1.5, 7.3 Hz, 1H), 4.29 – 4.27
(m, 1H), 3.89 (s, 1H), 3.82 (apparent t, J = 2.5 Hz, 1H), 3.80 (s, 3H), 3.79 (s, 1H); 13C
NMR ((CD3)2 CO, 125 MHz) δ160.4, 143.9, 140.4, 129.9, 119.4, 115.0, 112.8, 106.1,
101.9, 81.6, 69.5, 68.7, 66.6, 55.5. HRMS (m/z): [M+Na]+ Calcd. for C14H16O5Na,
287.0895; Found 287.0887 (∆ 0.8 mmu).
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(2R,4aR,8S,8aS)-2-(4-(dimethylamino)phenyl)-4,4a,8,8a-tetrahydropyrano[3,2d][1,3]dioxin-8-ol (67):
Treatment of 16 (0.5 g, 2.2 mmol) with p-(N,N-dimethylamino)benzaldehyde (0.5 g, 3.3
mmol) and p-toluenesulfonic acid (14.6 mg, 0.08 mmol) in toluene-DMF yielded a crude
mixture. Column chromatography (SiO2, a 1:1 ratio of ethyl acetate to hexanes) afforded
a white solid (0.01 g, 0.04 mmol, 2% yield): mp = 133-135 0C. [α]D24 -29 (c 0.2, CH2Cl2).
1H

NMR (CD3CN, 500 MHz) δ7.31 (d, J = 8.8 Hz, 1H), 6.73 (d, J = 8.8 Hz, 1H), 6.34 (d,

J = 6.4 Hz, 1H), 5.55 (s, 1H), 4.73 (d, J = 5.9 Hz, 1H), 4.35 (d, J = 6.9 Hz, 1H), 4.23 (d,
J = 6.35 Hz, 1H), 3.81 – 3.77 (m, 2H), 3.73 (dd, J = 6.8, 15.7 Hz, 1H), 2.94 (s, 6H); 13C
NMR ((CD3)2CO, 125 MHz) δ151.9, 144.0, 128.0, 126.9, 112.3, 106.1, 102.8, 81.5,
69.7, 68.7, 66.7, 66.6, 40.5. HRMS (m/z): [M+H]+ Calcd. for C15H20NO4, 278.1392;
Found 278.1396 (∆ 0.4 mmu).
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(2R,4aR,8S,8aS)-2-(4-(methylthio)phenyl)-4,4a,8,8a-tetrahydropyrano[3,2-d][1,3]dioxin8-ol (68):
Treatment of 16 (0.5 g, 2.2 mmol) with p-(methylthio)benzaldehyde (0.44 mL, 3.3 mmol)
and ZnCl2 yielded a crude mixture. Column chromatography (SiO2, a 1:1 ratio of ethyl
acetate to hexanes) afforded a white solid (0.09 g, 0.3 mmol, 15% yield). 1H NMR
((CD3)2CO, 500 MHz) δ7.45 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.3 Hz, 2H), 6.33 (ddd, J =
2.0, 8.1, 15.9 Hz, 1H), 5.68 (s, 1H), 4.91 – 4.80 (m, 1H), 4.44 (ddd, J = 2.0, 3.9, 9.3 Hz,
1H), 4.26 (dd, J = 4.9, 10.5 Hz, 1H), 4.11 – 3.98 (m, 1H), 3.71 (apparent t, J = 10.3 Hz,
1H), 3.60 (apparent dt, J = 4.9, 9.8 Hz, 1H), 2.50 (s, 3H) ; 13C NMR ((CD3)2CO, 125
MHz) δ165.3, 152.8, 146.2, 144.2, 139.5, 131.3, 126.8, 125.5, 100.2, 80.3, 71.3, 65.1,
61.2, 14.1. HRMS (m/z): [M+H]+ Calcd. for C14H16O4S, 303.0651; Found 303.0658 (∆
0.7 mmu).

156

(2R,4aR,8S,8aS)-2-(4-(trifluoromethyl)phenyl)-4,4a,8,8a-tetrahydropyrano[3,2d][1,3]dioxin-8-ol (70):
Treatment of 16 (0.5 g, 2.2 mmol) with p-(trifluoromethyl)benzaldehyde (0.45 mL, 3.3
mmol) and ZnCl2 (0.06 g, 0.44 mmol ) yielded a crude mixture. Column chromatography
(SiO2, a 1:1 ratio of ethyl acetate to hexanes) afforded a white solid (0.03 g, 0.1 mmol;
5% yield). 1H NMR ((CD3)2CO, 500 MHz) δ7.92 (d, J = 19.1 Hz, 2H), 7.77 (d, J = 8.3 Hz,
2H), 6.77 ( d, J = 5.9 Hz, 1H), 5.95 (s, 1H), 4.58 (apparent dt, J = 0.1, 5.4 Hz, 1H), 4.23
(dd, J = 6.4, 10.0 Hz, 1H), 3.95 (dd, J = 2.0, 12.2 Hz, 1H), 3.79 (dd, J = 4.9, 12.5 Hz,
1H), 3.47 (ddd, J = 2.0, 5.3, 10.0 Hz, 1H); 13C NMR ((CD3)2CO, 125 MHz) δ149.4,
144.0, 128.7, 126.2, 126.1, 125.9, 102.6, 99.1, 77.8, 70.8, 70.6, 61.3; 19F ((CD3)2CO,
400 MHz) δ63.2. HRMS (m/z): [M+Na]+ Calcd. for C14H13O4 F3Na, 325.0664; Found
325.0679 (∆ 1.5 mmu).
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Preparation of (2R,3S,4S)-2-(((4-methoxybenzyl)oxy)methyl)-3,4-dihydro-2H-pyran-3,4diol (72):
To a solution of 12 (0.29 g, 1.1 mmol) in CH2Cl2 (12.5 mL) at 0 0C, triethylsilane (0.87
mL, 5.4 mmol) was added followed by trifuluoroacetic acid (0.42 mL, 5.44 mmol). The
reaction was stirred at 0 0C for 1 hour and warmed to room temperature and stirred for
an additional 2 h. The reaction was quenched with a saturated solution of NaHCO3, and
was extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were washed with
brine (100 mL) and dried over MgSO4. The dried organic layer was concentrated in
vacuo and the residue was purified with column chromatography (SiO2, a 1:1 ratio of
ethyl acetate to hexanes) to afford a clear viscous liquid (0.21 g, 0.8 mmol, 72% yield):
mp = 54-56 0C. [α]D24 +35 (c 0.5, CH2Cl2). 1H NMR ((CD3)2CO, 500 MHz) δ7.29 (d, J =
8.8 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 6.28 (dd, J = 2.0, 5.9 Hz, 1H), 4.66 (dd, J = 2.5,
6.4 Hz, 1H), 4.49 (s, 2H), 4.12 (apparent dt, J = 2.0, 6.7 Hz, 1H), 3.87 – 3.81 (m, 2H),
3.78 (s, 3H), 3.74 (dd, J = 5.4, 10.3 Hz, 1H), 3.62 (dd, J = 6.8, 9.5 Hz, 1H); 13C NMR
((CD3)2CO, 125 MHz) δ160.6, 144.5, 132.2, 130.4, 114.9, 105.3, 79.4, 74.0, 71.4, 70.5,
61.9, 56.0. HRMS (m/z): [M+Na]+ Calcd. for C14H18O5Na, 289.1052; Found 289.1046 (∆
0.6 mmu).
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